,PageNo,Text
0,page_0,"N C T0 3 4 4 1 5 8 1 St u d y I D: 3 0 3 0 -4 0 1 -0 0 2 Titl e: A n O p e n -L a b el Pil ot St u d y of El u x a d oli n e i n P arti ci p a nt s wit h Irrit a bl e B o w el S y n dr o m e wit h Di arr h e a (I B S -D) W h o H a v e E vi d e n c e of Bil e A ci d M al a b s or pti o n ( B A M) Pr ot o c ol D at e: A pril 1 7, 2 0 1 9"
1,page_1,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1Title P a ge Pr ot oc ol Title: 3 0 3 0 -4 0 1 -0 0 2: A n O pe n -L a bel Pil ot St u d y of El u x a d oli ne i n P artici p a nts wit h Irrit a ble B o wel S y n dr o me wit h Di arr he a (I B S -D) W h o H a ve E vi de nce of Bile Aci d M al a bs or pti o n ( B A M) A m e n d me nt N u m ber: 2 Brief Pr ot oc ol Title: 3 0 3 0 -4 0 1 -0 0 2 E L X B A M St u d y Pr o d uct: El u x a d oli ne S p o ns or N a me a n d Le g al Re gistere d A d dress: Aller g a n S ales, 5 Gir al d a F ar ms, M a dis o n, N J 0 7 9 4 0, U nite d St ates; Aller g a n Li mite d, 1st F l o or M arl o w I nter n ati o n al, T he P ar k w a y, M arl o w, B uc ki n g h a ms hire S L 7, 1 Y L Aller g a n S ales, 5 Gir al d a F ar ms, M a dis o n, N J 0 7 9 4 0, U nite d St ates Re g ul at or y A ge nc y I de ntif yi n g N u m ber(s): I ND 7 9, 2 0 1 4 E mer ge nc y Tele p h o ne N u m ber: Refer t o t he st u d y c o nt act s p a ge S A E Re p orti n g F a x N u m ber/ E m ail: B usi ness U nit/ Or g a niz ati o n E m ail F a x Aller ga n P har mace uticals A p pr o v al D ate: 1 7 A pril 2 0 1 9 A me n d me nt 1 Date: 0 5 J u ne 2 0 1 8 Ori gi nal Pr ot oc ol Date: 1 9 Oct o ber 2 0 1 7 S p o ns or Si g n at or y: Si g nat ures of t he s p o ns or si g nat ories are c ollecte d o n t he pr ot oc ol a p pr o val f or m. V P, Cli nical De vel o p me nt – GI T hera p y Area Hea d"
2,page_2,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2Pr ot oc ol A me n d me nt S u m m ar y of C h a n ges Ta ble D O C U M E N T HI S T O R Y D oc u me nt D ate A m e n d me nt 2 1 7 A pril 2 0 1 9 A me n d me nt 1 0 5 J u ne 2 0 1 8 Ori gi nal Pr ot oc ol 1 9 Oct o ber 2 0 1 7 P ur p ose of A me n d me nt T he p ur p ose of Pr ot oc ol A me n d me nt 2 f or 3 0 3 0 -4 0 1 - 0 0 2 ( date d 1 7 A pril 2 0 1 9 ) is t o reflect t he defi niti o n of B A M base d o n t he m ost rece nt literat ure. T he f oll o wi n g is a s u m mar y of c o nte nt-orie nte d c ha n ges t hat were ma de. Stri ket hr o u g h te xt de n otes te xt re m o ve d a n d b ol de d te xt de n otes a d de d te xt. A d diti o nal a d mi nistrati ve e dits were als o ma de, b ut n ot s pecificall y n ote d (e g, c orrecte d s pelli n g, p u nct uati o n, gra m mar, a b bre viati o n, a n d st yle err ors) i ncl u di n g gl o bal e dits re q uire d f or c o nsiste nc y."
3,page_3,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3T a ble 1 – 1 S u m m ar y of C h a n ges i n Pr ot oc ol A me n d me nt 2 Secti o n N o. a n d N a meDescri pti o n of C h a n ge R ati o n ale Title Pa geA d de d Aller ga n U K, Marl o w S p o ns or A d dress t o facilitate i ncl usi o n of e x-U S sites i n t he st u d yU p date t o ali g n wit h c urre nt Aller ga n sta n dar d Secti o n 5. 4 Scie ntific Rati o nale f or St u d y Desi g nU p date d wit h rati o nale f or use of b ot h ser u m 7 α C 4 testi n g a n d meas ure me nt of fecal bile aci ds t o deter mi ne B A M stat us.T o u p date defi niti o n of B A M base d o n t he m ost rece nt literat ure S y n o psis a n d Secti o n 6. 1 I ncl usi o n CriteriaA me n de d I C 1. 0 1: Partici pa nt is a ma n or w o m a n a ge d 1 8 t o 6 5 7 5 years, i ncl usi ve, at scree ni n g.A p pr o xi matel y 2 5 % of partici pa nts wit h c hr o nic diarr hea or diarr hea pre d o mi na nt irrita ble b o w el s y n dr o me are f o u n d t o ha ve bile aci d mala bs or pti o n. As t here is n ot a ge restricti o n i n de vel o pi n g bile aci d mala bs or pti o n, Aller ga n belie ve it is critical t o u n dersta n d h o w t his me dicati o n will affect t his partici pa nt p o p ulati o n . S y n o psis a n d Secti o n 6. 1 I ncl usi o n CriteriaA me n de d I C 2. 0 3: Pa rtici pa nts wit h e vi de nce of B A M Partici pa nts m ust ha ve at le ast o ne of t he f oll o wi n g res ults fr o m fasti n g ser u m 7 α C 4 le vel ≥ 5 2. 5 n g/ m L at scree ni n g or wit hi n 1 cale n dar year pri or t o scree ni n g.  f asti n g ser u m 7 a -h y dr o x y - 4-c h oleste n- 3-o ne ( 7 α C 4) le vel ≥ 5 2. 5 n g/ m L  t ot al fec al bile aci ds > 2 3 3 7 mi cr o m oles/ 4 8 h o urs  pri m ar y bile aci ds ( fec al C A a n d C D C A) ≥ 1 0 % i n a 4 8 h fec al c ollecti o n  pri m ar y bile aci ds ( fec al C A a n d C D C A) ≥ 4 % wit h t ot al fec al bile aci d ≥ 1, 0 0 0 m icr o m oles/ 4 8 hr N ote: Partici pa nts ma y be e nr olle d as B A M p ositi ve wit h o ut ser u m 7 α C 4 test res ults if t he y ha ve p ositi ve res ults fr o m 4 8 -h o ur meas ure me nt of t otal fecal bile aci ds w it hi n 1 cale n dar year pri or t oT o u p date defi niti o n of B A M base d o n t he m ost rece nt literat ure"
4,page_4,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4Secti o n N o. a n d N a meDescri pti o n of C h a n ge R ati o n ale scree ni n g, defi ne d b y t otal fecal B A > 2 3 3 7 micr o m oles/ 4 8 h o urs. S y n o psis a n d Secti o n 6. 1 I ncl usi o n CriteriaA me n de d I C 2 . 0 4: Partici pa nts wit h o ut B A M Partici pa nts m ust ha ve at le ast o ne of t he f oll o wi n g res ults fr o m fasti n g ser u m 7 α C 4 le vel ≤ 4 7. 1 n g/ m L at scree ni n g or wit hi n 1 cale n dar year pri or t o scree ni n g.  f asti n g ser u m 7 α C 4 le vel ≤ 4 7. 1 n g/ mL  f asti n g ser u m 7 α C 4 le vels > 4 7. 1 n g/ m L b ut < 5 2. 5 n g/ m L wit h fec al bile aci ds t h at are ne g ati ve f or bile aci d m al a bs or pti o n (i.e. d o n ot meet criteri a 2. 0 3 b ase d o n fec al bile aci ds le vel)  t ot al fec al bile aci ds ( B A) ≤ 2 3 3 7 m icr o m oles/ 4 8 h o urs  pri m ar y bile aci ds ( fec al C A an d C D C A ) < 1 0 % i n a 4 8 h fec al c ollecti o n  pri m ar y bile aci ds ( fec al C A a n d C D C A) < 4 % wit h t ot al fec al bile aci d < 1, 0 0 0 micr o m oles / 4 8 hr N ote: Partici pa nts ma y be e nr olle d as B A M ne gati ve wit h o ut ser u m 7 α C 4 test res ults if t he y ha ve ne gati ve res ults fr o m 4 8 -h o ur meas ure me nt of t otal fecal B A w it hi n 1 cale n dar year pri or t o scree ni n g, defi ne d b y t otal fecal B A < 2 2 0 0 micr o m oles/ 4 8 h o urs. Partici pa nts wit h fasti n g ser u m 7 α C 4 le vels > 4 7. 1 n g/ m L b ut < 5 2. 5 n g/ m L ma y be e nr olle d as partici pa nts wit h o ut B A M if wit hi n 1 cale n dar year pri or t o scree ni n g visit t he y ha d ne gati ve res ults fr o m 4 8-h o ur meas ure me nts of t otal fecal B A."
5,page_5,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5Ta ble of C o nte nts Pr ot oc ol A me n d me nt S u m m ar y of C h a n ges T a ble ....................................................................2 T a ble of C o nte nts ...........................................................................................................................5 T a ble of T a bles ...............................................................................................................................7 1. S y n o psis ............................................................................................................................8 2. Sc he d ule of Acti vities ( S o A) .........................................................................................1 3 3. I ntr o d ucti o n...................................................................................................................1 6 3. 1. St u d y Rati o nale...............................................................................................................1 7 3. 2. Bac k gr o u n d .....................................................................................................................1 7 3. 3. Be nefit/ Ris k Assess me nt ................................................................................................1 8 4. O bjecti ves a n d E n d p oi nts ............................................................................................1 9 5. St u d y Desi g n ..................................................................................................................2 1 5. 1. O verall Desi g n ................................................................................................................2 1 5. 2. Partici pa nt a n d St u d y C o m pleti o n..................................................................................2 2 5. 3. E n d of St u d y Defi niti o n..................................................................................................2 3 5. 4. Scie ntific Rati o nale f or St u d y Desi g n ............................................................................2 3 5. 5. J ustificati o n f or D ose...................................................................................................... 2 5 6. St u d y P o p ul ati o n ...........................................................................................................2 6 6. 1. I ncl usi o n Criteria ............................................................................................................2 6 6. 2. E xcl usi o n Criteria ...........................................................................................................2 8 6. 3. Lifest y le Restricti o ns ......................................................................................................3 0 6. 4. Scree n Fail ures ................................................................................................................3 0 7. Tre at me nts .....................................................................................................................3 2 7. 1. Treat me nts A d mi nistere d ................................................................................................3 2 7. 2. D ose M o dificati o n .......................................................................................................... 3 2 7. 3. Met h o d of Treat me nt Assi g n me nt.................................................................................. 3 2 7. 4. Bli n di n g/ Mas ki n g ...........................................................................................................3 3 7. 5. P re parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y................................................................3 3 7. 6. Treat me nt C o m plia nce.................................................................................................... 3 3 7. 7. C o nc o mita nt T hera p y .....................................................................................................3 3 7. 7. 1. Pr o hi bite d Treat me nts Bef ore a n d D uri n g t he St u d y ......................................................3 4 7. 7. 2. Per mitte d Treat me nts...................................................................................................... 3 4 7. 7. 3. Resc ue Me dici ne .............................................................................................................3 5 7. 8. Treat me nt after t he E n d of t he St u d y ..............................................................................3 6 8. Disc o nti n u ati o n/ Wit h dr a w al Criteri a .........................................................................3 7 8. 1. Disc o nti n uati o n of St u d y Treat me nt ...............................................................................3 7 8. 1. 1. Te m p orar y Disc o nti n uati o n ............................................................................................3 8 8. 1. 2. Rec halle n ge .....................................................................................................................3 8
6,page_6,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 68. 2. Wit h dra wal fr o m t he St u d y .............................................................................................3 8 8. 3. L ost t o F oll o w U p ...........................................................................................................3 9 9. St u d y Assess me nts a n d Pr oce d ures............................................................................. 4 0 9. 1. Efficac y Assess me nts .....................................................................................................4 3 9. 1. 1. Dail y IB S S y m pt o ms ......................................................................................................4 4 9. 1. 2. Irrita ble B o wel Sy n dr o me -Q ualit y of Life Q uesti o n naire ..............................................4 4 9. 1. 3. Ser u m 7 α C 4 Le vel ..........................................................................................................4 4 9. 2. A d verse E ve nts ...............................................................................................................4 5 9. 2. 1. Ti me Peri o d a n d Fre q ue nc y f or C ollecti n g A E a n d S A E I nf or mati o n .....................................................................................................................4 5 9. 2. 2. Met h o d of Detecti n g A Es a n d S A Es ..............................................................................4 5 9. 2. 3. F oll o w -u p of A Es a n d S A Es ...........................................................................................4 6 9. 2. 4. Re g ulat or y Re p orti n g Re q uire me nts f or S A Es...............................................................4 6 9. 2. 5. Car di o vasc ular a n d Deat h E ve nts ...................................................................................4 6 9. 2. 6. Disease -Relate d E ve nts a n d/ or Disease -Relate d O utc o mes N ot Q ualif yi n g as A Es or S A Es .............................................................................................4 7 9. 2. 7. Pre g na nc y ........................................................................................................................4 7 9. 2. 8. A d verse E ve nts of S pecial I nterest .................................................................................4 7 9. 2. 9. Me dicati o n Err ors ...........................................................................................................4 9 9. 3. Treat me nt of O ver d ose ...................................................................................................4 9 9. 4. Safet y Assess me nts.........................................................................................................4 9 9. 4. 1. P h y sical E xa mi nati o ns ....................................................................................................4 9 9. 4. 2. Vital Si g ns....................................................................................................................... 4 9 9. 4. 3. Cli nical Safet y La b orat or y Assess me nts ........................................................................5 0 9. 4. 4. S uici dal Ris k M o nit ori n g ................................................................................................5 0 9. 5. P har mac o ki netics ............................................................................................................5 0 9. 6. P har mac o d y na mics .........................................................................................................5 1 9. 7. Ge netics ..........................................................................................................................5 1 9. 8. Bi o mar ker s ......................................................................................................................5 1 9. 9. Healt h Ec o n o mics O R Me dical Res o urce Utilizati o n a n d Healt h Ec o n o mics....................................................................................................................... 5 1 1 0. St atistic al C o nsi der ati o ns ............................................................................................5 2 1 0. 1. Sa m ple Size Deter mi nati o n ...........................................................................................5 2 1 0. 2. P o p ulati o ns f or A nal y ses ................................................................................................5 2 1 0. 3. Statistical A nal y ses .........................................................................................................5 2 1 0. 3. 1. K e y Statistical Met h o d ol o g y...........................................................................................5 2 1 0. 3. 2. Efficac y A nalys es ...........................................................................................................5 3 1 0 . 3. 3. Safet y A nal ys es ...............................................................................................................5 4 1 0. 3. 4. P har mac o ki netic A nal y ses ..............................................................................................5 5 1 0. 3. 5. Ot her A nal ys es ................................................................................................................5 5 1 0. 3. 6. I nteri m A nalys es .............................................................................................................5 5 1 1. Refere nces ......................................................................................................................5 6
7,page_7,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 71 2. A p pe n dices .....................................................................................................................5 9 1 2. 1. A p pe n di x 1: A b bre viati o ns a n d Tra de mar ks ..................................................................5 9 1 2. 3. A p pe n di x 3: St u d y G o ver na nce C o nsi derati o ns.............................................................6 3 1 2. 4. A p pe n di x 4: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, E val uati n g, F oll o w -u p, a n d Re p orti n g .........................................................6 7 1 2. 5. A p pe n di x 5: C o ntrace pti ve G ui da nce a n d C ollecti o n of Pre g na nc y Inf or mati o n ...................................................................................................7 3 1 2. 6. A p pe n di x 6: L i ver Safety: S u g geste d Acti o ns a n d F oll o w -u p Assess me nts ...................................................................................................................7 5 1 2. 7. A p pe n di x 7: Sta n dar d Disc o nti n uati o n Criteria ..............................................................7 8 1 2. 8. A p pe n di x 8: St u d y Ta b ular S u m mar y ............................................................................8 0 1 2. 1 0. A p pe n di x 1 0: S u m mar y A da pte d fr o m G ui deli nes of t he U S M ulti -s ociet y Tas k F orce o n C ol orectal Ca ncer a n d Ot her C ol o n osc o p y Re q uire me nts............................................................................................8 8 1 2. 1 1. A p pe n di x 1 1: Brist ol St o ol F or m Scale ( B S F S) .............................................................9 0 1 2. 1 3. Pr ot oc ol A me n d me nt 1 S u m mar y .................................................................................1 0 0 Ta ble of Ta bles Ta ble 1- 1 S u m mar y of C ha n ges i n Pr ot oc ol A me n d me nt 1................................................ 3 Ta ble 5 - 1 St u d y Desi g n ..................................................................................................... 2 2 Ta ble 7- 1 Treat me nts A d mi nistere d .................................................................................. 3 2 Ta ble 7 - 2 Pr o hi bite d Treat me nts Bef ore a n d D uri n g t he St u d y ........................................ 3 4 Ta ble 1 0 - 1 A nal y sis P o p ulati o ns ......................................................................................... 5 2 Ta ble 1 0 -2 Statistical Met h o d ol o g y ..................................................................................... 5 3 Ta ble 1 0 - 3 Pri mar y Efficac y E n d p oi nt................................................................................ 5 3 Ta ble 1 0 -4 Sec o n dar y Efficac y E n d p oi nts .......................................................................... 5 4 Ta ble 1 2 - 1 Pr ot oc ol -Re q uire d Safet y L a b orat or y Assess me nts.......................................... 6 2"
8,page_8,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 81. S y n o psis Pr ot oc ol Title: 3 0 3 0 -4 0 1 -0 0 2: A n O pe n -L a bel Pil ot St u d y of El u x a d oli ne i n P artici p a nts wit h Irrit a ble B o wel S y n dr o me wit h Di arr he a (I B S -D) W h o H a ve E vi de nce of Bile Aci d M al a bs or pti o n ( B A M) Pr ot oc ol N u m ber: 3 0 3 0 -4 0 1 -0 0 2 Brief Title: 3 0 3 0 -4 0 1 -0 0 2 E L X B A M St u d y St u d y P h ase: P hase I V St u d y R ati o n ale: El u xa d oli ne was a p pr o ve d f or t he treat me nt of a d ult patie nts wit h I B S -D b y t he F D A a n d E M A i n 2 0 1 5 a n d 2 0 1 6 , res pecti vel y. Beca use t he P hase 3 c o nfir mat or y st u dies of el u xa d oli ne f or I B S - D were c o n d ucte d pri or t o t he iss ua nce of t he latest versi o n of t he R o me criteria ( R o me I V) a n d pri or t o t he p u blicati o n of t he fi nal E M A g ui deli ne o n irrita ble b o wel s yn dr o me ( I B S), t hese st u dies di d n ot pr os pecti vel y e xcl u de patie nts wit h e vi de nce of B A M. Baseli ne c haracteristics of t he P hase 3 I B S-D patie nt p o p ulati o n de m o nstrate d a hi g h pre vale nce of b ot h o besit y a n d pri or c h olec ystect o my. Gi ve n t he k n o w n ass ociati o n of hi g her b o d y mass i n de x (B MI ) wit h B A M a n d t hat c h olec ystect o my is a k n o w n ris k fact or f or B A M it is c o ncei va ble t hat s o me p orti o n of partici pa nts e nr olle d i n t h ose st u dies ma y ha ve ha d e vi de nce of B A M. Si nce t he el u xa d oli ne P hase 3 I B S -D st u dies di d n ot e val uate partici pa nt’s bile aci d a bs or pti o n stat us, it is u n k n o w n w het her t he effecti ve ness of el u xa d oli ne ma y be differe nt i n patie nts wit h e vi de nce of B A M. It is p ossi ble t hat t he o verall effects of el u xa d oli ne c o ul d ha ve bee n dil ute d b y a s u bset of n o n - res p o nsi ve partici pa nts s ufferi n g fr o m B A M f or w h o m a bile aci d se q uestra nt mi g ht ha ve bee n a m ore a p pr o priate treat me nt o pti o n. T he g oal of t he prese nt st u d y is t heref ore t o e val uate t he p ossi bilit y of a differe ntial effect of el u xa d oli ne o n altere d b o wel f u ncti o n i n I B S - D partici pa nts wit h a n d wit h o ut e vi de nce of B A M. T he o verall h y p ot hesis of t his st u d y is t hat t he efficac y of el u xa d oli ne is greater i n partici pa nts wit h o ut e vi de nce of B A M c o m pare d t o t h ose wit h e vi de nce of B A M."
9,page_9,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9O bjecti ves a n d E n d p oi nt s T he pri mar y a n d sec o n dar y st u d y o bjecti ves a n d t heir c orres p o n di n g e n d p oi nts are liste d i n t he ta ble bel o w. O bjecti ves E n d p oi nts Pri mar y  T o e val uate t he efficac y of el u xa d oli ne 1 0 0 m g BI D i n I B S -D partici pa nts wit h e vi de nce of B A M c o m pare d t o I B S-D partici pa nts wit h o ut e vi de nce of B A M C ha n ge fr o m baseli ne i n a vera ge B S F S sc ore o ver 4 we e ks of treat me nt peri o d  T o e val uate t he safet y a n d t olera bilit y of el u xa d oli ne 1 0 0 m g BI D i n I B S -D partici pa nts wit h e vi de nce of B A M a n d i n I B S -D partici pa nts wit h o ut e vi de nce of B A M E val uati o n of a d verse e ve nts, cli nical la b orat or y tests, vital si g ns, p h ysical e xa mi nati o ns Sec o n dar y  T o f urt her e val uate t he efficac y of el u xa d oli ne 1 0 0 m g BI D i n I B S -D partici pa nts wit h e vi de nce of B A M c o m pare d t o I B S -D partici pa nts wit h o ut e vi de nce of B A M C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y b o w el m o ve me nt fre q ue nc y d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y w orst a b d o mi nal pai n sc ores d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n t he 4- wee k a vera ge of dail y bl oati n g d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of n u m ber of dail y ur ge nt b o w el m o ve me nts d uri n g t he treat me nt peri o d  T he pr o p orti o n of partici pa nts wit h a n y fecal i nc o nti ne nce d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n I B S -Q O L sc ore at t he e n d of t he treat me nt peri o d  C ha n ge fr o m baseli ne i n ser u m 7 α C 4 le vels at t he e n d of t he treat me nt peri o d  T o e val uate t he p o p ulati o n P K of el u xa d oli ne i n I B S-D patie nts wit h a n d wit h o ut e vi de nce of B A M P o p ulati o n p har mac o ki netic para meters of el u xa d oli ne deter mi ne d fr o m plas ma c o nce ntrati o n data e xtra p olate d fr o m drie d bl o o d sa m ple a nal ysis 7 α C 4 = 7a -h y dr o x y - 4-c h oleste n- 3-o ne; B A M = bile aci d mala bs or pti o n; BI D = t wice dail y; B S F S = Brist ol St o ol F or m Scale; I B S- D = irrita ble b o wel s y n dr o me wit h diarr hea; I B S-Q O L = irrita ble b o wel s y n dr o me -q ualit y of life; P K = p har mac o ki netics . O ver all St u d y Desi g n: T his P hase I V st u d y will use a n o pe n-la bel, parallel- gr o u p, c o h ort-c o ntr olle d desi g n i n partici pa nts meeti n g t he R o me IV criteria f or I B S -D wit h a n d wit h o ut e vi de nce of B A M. Partici pa nts will be assi g ne d t o 1 of 2 c o h orts base d o n t heir B A M stat us. As far as p ossi ble t he 2 c o h orts will be matc he d b y a ge, ge n der a n d se verit y of s ym pt o ms. 1. C o h ort 1: I B S -D partici pa nts wit h e vi de nce of B A M treate d wit h el u xa d oli ne 1 0 0 m g oral ta blets t wice daily ( BI D ) wit h f o o d."
10,page_10,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 02. C o h ort 2: I B S -D partici pa nts wit h o ut e vi de nce of B A M treate d wit h el u xa d oli ne 1 0 0 m g oral ta blets BI D wit h f o o d. St u d y Desi g n Peri o d Scree ni n gaPretre at m e ntaO pe n -L a bel Tre at me nt P ost -Tre at m e nt D ur ati o n 0- 2 w ee ks 2- 3 w ee ks 4 w ee ks 2 w ee ks Wee k Scree ni n g Pretreat me nt Baseli ne Wee k 2bWee k 4 ( E O T/ E T)Wee k 6b ( F oll o w-u p) St u d y Visit 1 2 3 4 5 6 St u d y D a y 1 1 5 ( ± 2) 2 9 ( ± 2) Visit 5 + 1 4 da ys (± 7 ) 7 α C 4 = 7a -h y dr o x y - 4-c h oleste n- 3-o ne; B A = bile aci d aScree ni n g a n d pretreat me nt peri o ds ma y be c o m bi ne d . if res ults of fasti n g ser u m 7 α C 4 test or 4 8-h o ur fecal B A c ollecti o n c o n d ucte d wit hi n 1 cale n dar year fr o m scree ni n g are a vaila ble at t he ti me of t he c o m bi ne d visit or res ults fr o m fasti n g ser u m 7 α C 4 test are a vaila ble pri or t o t he start of st u d y treat me nt.. bM a y be d o ne o ver t he p h o ne. T he t otal d urati o n of st u d y partici pati o n f or eac h part ici pa nt will be u p t o 1 1 wee ks. Ke y i ncl usi o n criteri a: 1. A d ult me n or w o me n a ge d 1 8 t o 7 5 ye ars i ncl usi ve wit h a dia g n osis of I B S - D per R o me I V criteri a. 2. Partici pa nts wit h e vi de nce of B A M m ust ha ve at least o ne of t he f oll o wi n g at scree ni n g or wit hi n 1 ca le n dar ye ar pri or t o scree ni n g :  fasti n g ser u m 7a -h y dr o x y - 4-c h oleste n- 3-o ne ( 7 α C 4) le vel ≥ 5 2. 5 n g/ m L  t otal fecal bile aci ds > 2 3 3 7 micr o m oles/ 4 8 h o urs  pri mar y bile aci ds (fecal C A a n d C D C A) ≥ 1 0 % i n a 4 8 h fecal c ollecti o n  pri mar y bile aci ds (fecal C A a n d C D C A) ≥ 4 % wit h t otal fecal bile aci d ≥ 1, 0 0 0 micr o m oles/ 4 8 hr 3. .Partici pa nts wit h o ut B A M m ust ha ve at least o ne of t he f oll o wi n g at scree ni n g or wit h i n 1 cale ndar y ear pri or t o scree ni n g :  fasti n g ser u m 7 α C 4 le vel ≤ 4 7. 1 n g/ m L  fasti n g ser u m 7 α C 4 le vels > 4 7. 1 n g/ m L b ut < 5 2. 5 n g/ m L wit h fecal bile aci ds t hat are ne gati ve f or bile aci d mala bs or pti o n (i.e. d o n ot meet criteria 2. 0 3 base d o n fecal bile aci ds le vel)  t otal fecal bile aci ds ( B A) ≤ 2 3 3 7 micr o m oles/ 4 8 h o urs"
11,page_11,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 1 pri mar y bile aci ds (fecal C A a n d C D C A) < 1 0 % i n a 4 8 h fecal c ollecti o n  pri mar y bile aci ds (fecal C A a n d C D C A) < 4 % wit h t otal fecal bile aci d < 1, 0 0 0 micr o m oles / 4 8 hr 4. A n a vera ge dail y Brist ol St o ol F or m Scale ( B S F S ) sc ore ≥ 5. 0 or ≥ 2 5 % of diar y e ntr y d a y s wit h a B S F S sc ore of 6 or 7 d uri n g t he 1 4 da y s pri or t o Da y 1. 5. W o me n of c hil d b eari n g p ote ntial m ust use h or m o nal or d o u ble barrier c o ntrace pti o n or mai ntai n a m o n o ga m o us relati o ns hi p wit h a vasect o mize d male part ner fr o m t he date of i nf or me d c o nse nt u ntil 2 4 h o urs after fi nal d ose of st u d y dr u g. 6. C o m plete d t he electr o nic diar y ( e Diar y) o n ≥ 1 0 of t he 1 4 da y s pri or t o Da y 1. 7. H as n ot use d l o pera mi de resc ue me dicati o n o n > 3 of t he 1 4 da y s pri or t o Da y 1. Ke y e xcl usi o n criteri a: 1. A dia g n o sis of I B S wit h a s u bt ype of irrita ble b o wel s y n dr o me wit h c o nsti pati o n (I B S- C), mi xe d I B S, or u ns u bt y pe d I B S per R o me I V criteria. 2. D oes n ot ha ve a gall bla d der. 3. K n o w n or s us pecte d biliar y d uct o b str ucti o n, or s p hi ncter of O d di disease or d ysf u ncti o n. (Partici pa nts wit h a hist or y of gallst o nes ma y be e nr olle d). 4. H ist or y of alc o h olis m, alc o h ol a b use or alc o h ol a d dicti o n, or dri n ks m ore t ha n 3 alc o h olic be vera ges per da y . 5. H ist or y of pa ncreatitis; str uct ural diseases of t he pa ncreas, i ncl u di n g k n o w n or s us pecte d pa ncreatic d uct o bstr ucti o n. 6. H ist or y of mil d, m o derate, or se vere he patic i m pair me nt acc or di n g t o C hil d-P u g h classificati o n. H ist or y or c urre nt dia g n osis of i nfla m mat or y or i m m u ne-me diate d gastr oi ntesti nal ( GI ) dis or ders . 7. C eliac disease or a p ositi ve ser o l o gical test f or celiac disease. 8. K n o w n lact ose or fr uct ose i nt olera nce ass ociate d wit h diarr hea, a b d o mi nal pai n or disc o mf ort, t hat c o ul d c o nf o u n d assess me nts i n t he st u d y. 9. W o me n w h o are c urre ntl y pre g na nt or n ursi n g, or pla n t o bec o me pre g na nt or n urse d uri n g t he st u d y. 1 0. K n o w n aller gies or h y perse nsiti vit y t o o pi oi ds. N u m ber of P artici p a nt s: T here will be 2 4 partici pa nts e nr olle d i n t he st u d y , 1 2 partici pants wit h e vi de nce of B A M a n d 1 2 partici pa nts wit h o ut e vi de nce of B A M. N u m ber of Sites: T he st u d y will be c o n d ucte d at 1 st u d y site i n t he U nite d States."
12,page_12,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 2Tre at me nt Gr o u ps a n d St u d y D ur ati o n: T he t otal d urati o n of t he st u d y is u p t o 1 1 wee ks, w hic h i ncl u des: scree ni n g peri o d ( 0 - 2 wee ks), pretreat me nt peri o d ( 2 -3 wee ks), 4 -wee k o pe n -la bel treat me nt peri o d, a n d 2-wee k p ost -treat me nt safety f oll o w-u p peri o d ."
13,page_13,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 32. Sc he d ule of Acti vities ( S o A)
14,page_14,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 4
15,page_15,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 5
16,page_16,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 63. I ntr o d ucti o n Irrita ble b o wel s yn dr o me (I B S) is o ne of t he m ost c o m m o n a n d m ost wi del y st u die d f u ncti o nal gastr oi ntesti nal dis or ders ( F GI D; L o n gstret h 2 0 0 6 ; C he y 2 0 1 5). I B S is c haracterize d by a b d o mi nal pai n ass ociate d wit h altere d b o wel m o ve me nt s y m pt o ms a n d is s u bcate g orize d base d o n st o ol patter ns ( Dr oss ma n 2 0 0 6 ). F o ur differe nt s u bt ypes are defi ne d w hic h i ncl u de I B S wit h: diarr hea (I B S -D), c o nsti pati o n (I B S -C), b ot h c o nsti pati o n a n d diarr hea (I B S -M), or u ns pecifie d (I B S-U). As a n F GI D, I B S lac ks a n u n derl yi n g or ga nic ca use (s uc h as a str uct ural, i nfla m mat or y , or bi oc he mical a b n or malit y ) a n d is dia g n ose d pri maril y base d o n patie nts’ s ym pt o m re p orts per t he R o me Dia g n ostic Criteria f or F u ncti o nal Gastr oi ntesti nal Dis or ders ( R o me). T he gl o bal pre vale nce of I B S is esti mate d t o be 1 1. 2 % (L o vell 2 0 1 2 ; C he y 2 0 1 5). I B S is ass ociate d wit h si g nifica nt i m pair me nt i n q ualit y of life a n d hi g h rates of c o m or bi d c o n diti o ns (Gral ne k 2 0 0 0 ), w hic h i m p o ses a si g nifica nt s oci oec o n o mic b ur de n t o s ociet y (H ulisz 2 0 0 4 ; Paré 2 0 0 6 ). T he pat h o p h ys i ol o g y of I B S is n ot c o m pletel y u n derst o o d b ut is t h o u g ht t o be m ultifact orial, wit h ge netics, a b n or mal g ut m otilit y , visceral h yperse nsiti vit y , psyc h os ocial distress, altere d g ut micr o bi o me, a n d brai n -g ut i nteracti o n pla y i n g i m p orta nt r oles i n its de vel o p me nt (Ca milleri 2 0 1 2 ; C he y 2 0 1 5). Im p orta nt t o t he diarr heal s u bt ype of I B S, it is i ncreasi n gl y rec o g nize d t hat bile aci d mala bs or pti o n ( B A M) ma y be a p ote ntial ca use of c hr o nic diarr hea (Aziz 2 0 1 5 ; Baj or 2 0 1 5 ; Ca milleri 2 0 1 5 ; Vale nti n 2 0 1 6 ). I n B A M, t he fail ure t o a de q uately rea bs or b c o nj u gate d bile salts i n t he ter mi nal ile u m lea ds t o e xcess bile aci ds e nteri n g t he c ol o n w here t he y sti m ulate c ol o nic secreti o n a n d m otilit y (Ca milleri 2 0 1 4 ). Sy m pt o ms of B A M prese nt as water y diarr hea, bl oati n g, fecal ur ge nc y a n d fecal i nc o nti ne nce, w hic h cl osel y o verla p t he s ym pt o ms of f u ncti o nal diarr hea a n d I B S -D ( Isla m 2 0 1 2 ). Rece nt e vi de nce s u g gests t hat u p t o 1/ 3 of patie nts w h o meet t he R o me criteria f or I B S -D ha ve e vi de nce of B A M base d pri maril y o n 7 5Sele ni u m -h o m oc h olic aci d ta uri ne ( Se H C A T) rete nti o n testi n g ( We dla ke 2 0 0 9 ; Aziz 2 0 1 5 ; Baj or 2 0 1 5 ). O verall, I B S-D patie nts wit h a n d wit h o ut e vi de nce of B A M a p pear hi g hl y si milar i n de m o gra p hic c haracteristics a n d assess me nts of well -bei n g, e xce pt t hat patie nts wit h B A M te n d t o ha ve hi g her B MIs (Ca milleri 2 0 1 4a ; Aziz 2 0 1 5 ). T he p ote ntial o verla p of I B S -D a n d B A M ma y ha ve i m p orta nt i m plicati o ns f or cli nical practice, es peciall y if a n altere d treat me nt c o urse w o ul d be c o nsi dere d. Re c o g nizi n g t his, t he m ost rece nt versi o n of t he R o me dia g n ostic criteria f or I B S -D iss ue d i n 2 0 1 6 ( R o me I V) n o w rec o m me n ds a n asses s me nt of B A M stat us as a p ote ntial ca use of c hr o nic, water y diarr hea ( Lac y 2 0 1 6). F or patie nts wit h e vi de nce of B A M, a bile aci d se q uestra nt ma y be a n a p pr o priate treat me nt o pti o n, at least f or t he diarr heal s y m pt o ms, t h o u g h p o or t olera bilit y a n d c o m plia nce ca n be pr o ble matic f or t he m ost ec o n o mical bile aci d bi n di n g a ge nt c h olest yra mine ( Ca milleri 2 0 1 4 ). T he p ote ntial I B S-D/ B A M o verla p als o has i m plicati o ns f or cli nical researc h, partic ularl y if a pr o d uct bei n g de vel o pe d f or I B S -D has a differe nt be nefit -ris k pr ofile i n patie nts wit h e vi de nce of B A M. S uc h a sit uati o n c o ul d lea d t o a n u n deresti mate of a pr o d uct’s real effecti ve ness i n I B S -D, es peciall y if a lar ge pr o p orti o n of patie nts i n a st u d y ha ve o verla p pi n g B A M a n d are u nres p o nsi ve t o treat me nt. T o eli mi nate t his p ossi bilit y, t he Se pte m ber 2 0 1 4 E M A g ui deli ne ( C P M P/ EW P/ 7 8 5/ 9 7/ Re v. 1) o n t he de vel o p me nt of dr u gs f or I B S rec o m me n ds e xcl u di n g patie nts wit h B A M fr o m I B S -D st u dies."
17,page_17,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 73. 1. St u d y R ati o n ale El u xa d oli ne was a p pr o ve d f or t he treat me nt of a d ult patie nts wit h I B S -D b y t he F D A a n d E M A i n 2 0 1 5 a n d 2 0 1 6 , res pecti vel y. Beca use t he P hase 3 c o nfir mat or y st u dies of el u xa d oli ne f or I B S - D were c o n d ucte d pri or t o t he iss ua nce of t he latest versi o n of t he R o me criteria ( R o me I V) a n d pri or t o t he p u blicati o n of t he fi nal E M A g ui deli ne o n I B S, t hese st u dies di d n ot pr os pecti vel y e xcl u de patie nts wit h e vi de nce of B A M. Baseli ne c haracteristics of t he P hase 3 I B S -D patie nt p o p ulati o n de m o nstrate d a hi g h pre vale nce of b ot h o besit y a n d pri or c h olec ystect o my. Gi ve n t he k n o w n ass ociati o n of hi g her B M I wit h B A M (Ca milleri 2 0 1 4a ; Aziz 2 0 1 5 ) a n d t hat c h olec ystect o my is a k n o w n ris k fact or f or B A M ( Walters 2 0 1 0 ), it is c o ncei va ble t hat s o me p o rti o n of partici pa nts e nr olle d i n t h ose st u dies ma y ha ve ha d e vi de nce of B A M. Si nce t he el u xa d oli ne P hase 3 I B S -D st u dies di d n ot e val uate partici pa nt’s bile aci d a bs or pti o n stat us, it is u n k n o w n w het her t he effecti ve ness of el u xa d oli ne ma y be differe nt i n patie nts wit h e vi de nce of B A M. It is p ossi ble t hat t he o verall effects of el u xa d oli ne c o ul d ha ve bee n dil ute d b y a s u bset of n o n -res p o nsi ve patie nts s ufferi n g fr o m B A M f or w h o m a bile aci d se q uestra nt mi g ht ha ve bee n a m ore a p pr o priate treat me nt o pti o n. T he g oal of t he prese nt st u d y is t heref ore t o e val uate t he p ossi bilit y of a differe ntial effect of el u xa d oli ne o n altere d b o wel f u ncti o n i n I B S -D partici pa nts wit h a n d wit h o ut e vi de nce of B A M. T he o verall h y p ot hesis of t his st u d y is t hat t he efficac y of el u xa d oli ne is greater i n partici pa nts wit h o ut e vi de nce of B A M c o m pare d t o t h ose wit h e vi de nce of B A M. 3. 2. B ac k gr o u n d El u xa d oli ne is a l ocall y acti ve mi xe d m u -o pi oi d rece pt or (µ O R ) a g o nist, ka p pa -o pi oi d rece pt or ( κ O R) a g o nist, a n d delta-o pi oi d rece pt or ( δ O R) a nta g o nist wit h l o w oral bi oa vaila bilit y. El u xa d oli ne has bee n a p pr o ve d f or t he treat me nt of a d ult patie nts wit h I B S -D i n t he U nite d States, t he E ur o pea n U ni o n, a n d Ca na da, a m o n g ot her re gi o ns. El u xa d oli ne has gastr oi ntesti nal (GI ) tra nsit i n hi biti n g acti vit y t hat is c o nsiste nt wit h its pri mar y p har mac ol o gical pr ofile as a µ O R a g o nist. T he mi xe d p har mac ol o gical pr ofile of el u xa d oli ne ma y miti gate t he ris k of c o nsti pati o n effects t hr o u g h u n o p p ose d µ O R a g o nis m as see n wit h a ge nts s uc h as l o pera mi de, t hr o u g h a nta go nis m of t he δ O R ( Wa de 2 0 1 2 ). El u xa d oli ne has bee n de m o nstrate d t o be effecti ve i n treati n g t he a b d o mi nal pai n a n d diarr heal s ym pt o ms of patie nt s wit h I B S-D wit h a n acce pta ble ris k pr ofile ( El u xa d oli ne In vesti gat or’s Br oc h ure). T he efficac y a n d safety i n I B S -D patie nts was c o nfir me d i n 2 ra n d o mize d, m ultice nter, m ulti nati o nal, d o u ble -bli n d, place b o -c o ntr olle d P ha se 3 st u dies i n a t otal of 2 4 2 6 pat ie nts meeti n g t he R o me III criteria f or I B S-D (st u dies I B S -3 0 0 1 a n d I B S -3 0 0 2; Le m b o 2 0 1 6 a n d VI B E R ZI ™ PI 2 0 1 7 ). T he pri mar y e n d p oi nt of t he P hase 3 st u dies was defi ne d b y t he si m ulta ne o us i m pr o ve me nt i n t he dail y w orst a b d o mi nal pai n sc ore b y ≥ 3 0 % c o m pare d wit h baseli ne wee kl y a vera ge a n d a re d ucti o n i n t he Brist ol St o ol F or m Scale ( B S F S) t o < 5 o n at least 5 0 % of da ys wit hi n a 1 2-wee k treat me nt peri o d ( F D A e n d p oi nt) a n d a 2 6 -wee k treat me nt peri o d ( E M A e n d p oi nt)."
18,page_18,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 83. 3. Be nefit/ Ris k Assess me nt El u xa d oli ne 1 0 0 m g t wice dail y ( BI D) de m o nstrate d si g nifica ntl y greater c o m p osite res p o n der rates as c o m pare d wit h place b o o ver 1 2 wee ks a n d 2 6 wee ks of treat me nt. El u xa d oli ne 7 5 m g BI D de m o nstrate d si g nifica ntl y greater res p o n der rates t ha n place b o o ver 1 2 wee ks i n b ot h st u dies, a n d greater res p o n der rates t ha n place b o o ver 2 6 wee ks of treat me nt i n st u d y IB S 3 0 0 2, b ut n ot i n st u d y IB S 3 0 0 1 ( Le m b o 2 0 1 6 , VI B E R ZI P I 2 0 17 ). T he treat me nt effect of el u xa d oli ne o ver place b o was o bser ve d wit hi n t he first wee k a n d was mai ntai ne d t hr o u g h o ut t he 2 6 -wee k assess me nt peri o d. Ot her a b d o mi nal s y m pt o ms a n d meas ures of b o wel f u ncti o n were als o si g nifica ntl y i m pr o ve d wit h el u xa d oli ne treat me nt as c o m pare d wit h place b o. Lo n git u di nal a nal ys es de m o nstrate d t hat dail y a b d o mi nal disc o mf ort sc ores were si g nifica ntl y l o wer t ha n place b o f or b ot h t he 7 5 m g a n d 1 0 0 m g el u xa d oli ne gr o u ps t hr o u g h Wee k 2 6. Dail y bl oati n g sc ores were si gnifica ntl y l o wer t ha n place b o wit h el u xa d oli ne 1 0 0 m g after Wee k 1 2 ( Wee ks 1 6, 2 0, 2 4, a n d 2 6). Ris ks f or fre q ue nc y of b o wel m o ve me nts a n d ur ge nc y e pis o des were als o si g nifica ntl y l o wer t ha n place b o f or b ot h el u xa d oli ne d oses t hr o u g h Wee k 2 6 of treat me nt. A d diti o nall y , b ot h d oses of el u xa d oli ne were si g nifica ntl y s u peri or t o place b o wit h res pect t o t he e n d p oi nts of a de q uate relief of I B S sy m pt o ms, sc ores f or gl o bal s y m pt o ms, a n d sc ores o n t he I B S -Q ualit y of Life q uesti o n naire. El u xa d oli ne was si g nifica ntl y s u peri or t o place b o i n all s u b p o p ulati o ns e x pl ore d (Le m b o 2 0 1 6 ). I n cli nical st u dies, el u xa d oli ne ha d a fa v ora ble t olera bilit y pr ofile wit h l o w rates of pre d o mi na ntl y GI A Es. T he m ost c o m m o nl y re p orte d A Es were c o nsti pati o n, nausea, a n d a b d o mi nal pai n. A p pr o xi matel y 5 0 % of c o nsti pati o n e ve nts occ urre d wit hi n t he first 2 wee ks of treat me nt, wit h m ost cases bei n g of mil d t o m o derate i nte nsit y . I nfre q ue nt, me dically i m p orta nt ris ks re p orte d wit h el u xa d oli ne i n cli nical st u dies wer e ( 1) mil d tra nsie nt pa ncreatitis or ra pi dl y re versi ble ele vati o n of tra nsa mi nases ass ociate d wit h a b d o mi nal pai n, b ot h c o nsiste nt wit h s p hi ncter of O d di ( S O) s pas m or biliar y sl u d ge, a n d ( 2) pa ncreatitis ass ociate d wit h hea v y alc o h ol c o ns u m pti o n. S o me of t hese e ve nts le d t o brief h os pitalizati o ns, b ut all ha d fa v ora ble o utc o mes wit h n o se q uelae. T here were 1 3 cases t hat were a dj u dicate d as S O s pas m wit h a n o verall occ urre nce rate of 0. 5 8 %. C h olec y stec t o my stat us was k n o w n i n 1 2 of t he 1 3 patie nts, a n d all 1 2 patie nts w here stat us was k n o w n ha d n o gall bla d der. I n t he p ost mar keti n g setti n g, se vere cases of ac ute pa ncreatitis, s o meti mes fatal, were o bser ve d f oll o wi n g t he use of el u xa d oli ne i n patie nts wit h o ut a gall bla d der. Beca use of t his, use of el u xa d oli ne i n patie nts wit h o ut a gall bla d der is c o ntrai n dicate d. M ore detaile d i nf or mati o n a b o ut t he k n o w n a n d e x pecte d be nefits a n d ris ks a n d reas o na bl y e x pecte d A Es of el u xa d oli ne ma y be f o u n d i n t he In vesti gat or’s B r oc h ure (I B) a n d/ or pac ka ge i nsert."
19,page_19,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 94. O bjecti ves a n d E n d p oi nts O bjecti ves E n d p oi nts Pri mar y  T o e val uate t he efficac y of el u xa d oli ne 1 0 0 m g BI D i n I B S -D partici pa nt s wit h e vi de nce of B A M c o m pare d t o I B S-D partici pa nt s wit h o ut e vi de nce of B A M C ha n ge fr o m baseli ne i n a vera ge B S F S sc ore o ver 4 we e ks of treat me nt peri o d  T o e val uate t he safet y a n d t olera bilit y of el u xa d oli ne 1 0 0 m g BI D i n I B S -D partici pa nt s wit h e vi de nce of B A M a n d i n I B S -D partici pa nt s wit h o ut e vi de nce of B A M E val uati o n of a d verse e ve nts, cli nical la b orat or y tests, vital si g ns, p h ysical e xa mi nati o ns Sec o n dar y  T o f urt her e val uate t he efficac y of el u xa d oli ne 1 0 0 m g BI D i n I B S -D partici pa nts wit h e vi de nce of B A M c o m pare d t o I B S -D partici pa nts wit h o ut e vi de nce of B A M C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y b o w el m o ve me nt fre q ue nc y d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y w orst a b d o mi nal pai n sc ores d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y bl oati n g d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of n u m ber of dail y ur ge nt b o w el m o ve me nts d uri n g t he treat me nt peri o d  T he pr o p orti o n of partici pa nt s wit h a n y fecal i nc o nti ne nce d uri n g t he treat me nt peri o d  C ha n ge fr o m baseli ne i n I B S -Q O L sc ore at t he e n d of t he treat me nt pe ri o d  C ha n ge fr o m baseli ne i n ser u m 7 α C 4 le vels at t he e n d of t he treat me nt peri o d  T o e val uate t he p o p ulati o n P K of el u xa d oli ne i n I B S-D patie nts wit h a n d wit h o ut e vi de nce of B A M. P o p ulati o n p har mac o ki netic para meters of el u xa d oli ne deter mi ne d fr o m plas ma c o nce ntrati o n data e xtra p olate d fr o m drie d bl o o d sa m ple a nal ysis 7 α C 4 = 7a -h y dr o x y - 4-c h oleste n- 3-o ne; B A M = bile aci d mala bs or pti o n; BI D = t w ice dail y; B S F S = Brist ol St o ol F or m Scale; I B S-D = irrita ble b o w el s y n dr o me wit h diarr hea; I B S-Q O L = irrit a ble b o wel s y n dr o me -q ualit y of life; P K = p har mac o ki netics Cli nic al H y p ot heses T he p ote ntial i ncl usi o n of partici pa nt s wit h e vi de nce of B A M i n t he el u xa d oli ne P hase 3 st u dies of I B S -D c o ul d ha ve le d t o a n u n deresti mati o n of el u xa d oli ne’s effects o n I B S -D, es peciall y if t he partici pa nt s’ B A M re prese nte d t he pri mar y ca use of t heir diarr heal sy m pt o ms. H o we ver, gi ve n its mec ha nis m of acti o n as a mi xe d μ O R/ κ O R a g o nist a n d δ O R a nta g o nist, el u xa d oli ne s h o ul d res ult i n re d uce d i ntesti nal m otilit y a n d secreti o ns irres pecti ve of a n y u n derl yi n g eti ol o g y (s uc h as u na bs or be d l u mi nal bile aci ds d ue t o B A M). It is t heref ore h yp ot hesize d t hat"
20,page_20,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 0el u xa d oli ne will ha ve si milar p har mac o d y n a mic effect s t o i ncrease st o ol c o nsiste nc y i n I B S-D partici pa nts wit h a n d wit h o ut e vi de nce of B A M.
21,page_21,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 15. St u d y Desi g n 5. 1. O ver all Desi g n T his is a P hase 4, o pe n -la bel, parallel-gr o u p, c o h ort c o ntr olle d st u d y t o e val uate t he efficac y, safety, t olera bility a n d p har mac o ki net ics of el u xa d oli ne i n partici pa nt s meeti n g t he R o me I V criteria f or I B S-D wit h a n d wit h o ut e vi de nce of B A M. T hi s st u d y will be c o m prise d of a 0 t o 2- wee k scree ni n g peri o d, a 2 t o 3- wee k pretreat me nt peri o d, a 4 -wee k o pe n -la bel treat me nt peri o d d uri n g w hic h ti me partici pa nt s will recei ve el u xa d oli ne 1 0 0 m g BI D, a n d a 2 -wee k p ost -treat me nt safet y f oll o w-u p. T here will be 2 4 partici pa nt s e nr olle d i n t he st u d y, 1 2 wit h e vi de nce of B A M a n d 1 2 wit h o ut e vi de nce of B A M.  C o h ort 1: I B S -D partici pa nt s wit h e vi de nce of B A M treate d wit h el u xa d oli ne 1 0 0 m g oral ta blets BI D wit h f o o d  C o h ort 2: I B S -D partici pa nt s wit h o ut e vi de nce of B A M treate d wit h el u xa d oli ne 1 0 0 m g oral ta blets BI D wit h f o o d As far as p ossi ble, t he 2 c o h orts will be matc he d b y a ge, ge n der a n d se verit y of hist oric s ym pt o ms base d o n t he i n vesti gat or's discreti o n. E val uati o n of I B S -D s y m pt o ms d uri n g t he pretreat me nt peri o d will esta blis h t he baseli ne of I B S -D se verit y a n d will c o nti n ue f or t he d urati o n of t he st u d y. Meas ure me nts of st o ol c o nsiste nc y sc ores a n d ot her I B S-D si g ns a n d s ym pt o ms will be meas ure d dail y usi n g a n electr o nic diar y (e Diar y). After scree ni n g pr oce d ures ha ve bee n perf or me d ( u p t o 2 wee ks), eli gi ble partici pa nt s will enter a p retreat me nt peri o d of 2 t o 3 wee ks. At t he be gi n ni n g of t he p retreat me nt peri o d partici pa nt s will recei ve i nstr ucti o ns f or c o m pleti n g t he e Diar y t o c ollect dail y i nf or mati o n relate d t o t heir I B S-D s y m pt o ms i ncl u di n g st o ol c o nsiste nc y (B S F S ), w orst a b d o mi nal pai n, a b d o mi nal bl oati n g, b o wel m o ve me nt fre q ue nc y , resc ue me dicati o n usa ge, n u m ber of e pis o des of ur ge nc y i n a da y, a n d n u m ber of e pis o des of fecal i nc o nti ne nce , if a n y. At t he c o ncl usi o n of t he pretreat me nt peri o d, partici pa nt s w h o meet t he st ud y e ntry criteria relate d t o st o ol c o nsiste nc y , e Diar y c o m plia nce, a n d resc ue l o pera mi de use will be e nr olle d t o recei ve a 4-wee k o pe n -la bel el u xa d oli ne 1 0 0 m g BI D treat me nt. Partici pa nt s e nr olle d i n t he t reat me nt p eri o d will ret ur n t o t he st u d y site f or st u d y visits at Wee k 2, Wee k 4 (e n d -of -treat me nt st u d y visit), a n d f or a p ost-treat me nt f oll o w-u p st u d y visit at Wee k 6. Tele p h o ne c o ntacts ma y be ma de t o partici pa nt s i n lie u of a n o n-site visit at Wee k 2. A c o m plete sc he d ule of acti vities ( S o A) is pr o vi de d i n Secti o n 2 . Partici pa nt s w h o disc o nti n ue fr o m t he st u d y bef ore t he Wee k 4 visit s h o ul d ret ur n t o t he st u d y site t o c o m plete t he early ter mi nati o n assess me nts as s o o n as p ossi ble after st o p pi n g t he st u d y dr u g. D uri n g t he o pe n -la bel treat me nt peri o d, partici pa nts will rec or d via t he e Diar y t heir dail y I B S-D s ym pt o ms i ncl u di n g st o ol c o nsiste nc y ( B S F S), w orst a b d o mi nal pai n, a b d o mi nal bl oa ti n g, b o wel m o ve me nt fre q ue nc y , resc ue me dicati o n usa ge, n u m ber of e piso des of ur ge nc y i n a da y, a n d n u m ber of e pis o des of fecal i nc o nti ne nce, if a ny."
22,page_22,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 2T he act ual e Diar y data e ntere d by t he partici pa nt s will n ot be pr o vi de d t o t he i n vesti gati ve site staff at a ny ti me d uri n g t he st u d y t o pre ve nt a n y p ote ntial bias i n s u bse q ue nt partici pa nt e ntries. H o we ver, peri o dic n otificati o ns will be ge nerate d t o i nf or m t he i n vesti gat or of partici pa nt s’ o n g oi n g c o m plia nce wit h e Diar y e ntries a n d t o alert i n vesti gat ors if partici pa nt s ha ve e x perie nce d e pis o des of c o nsti pati o n or ha ve re q uire d e xcessi ve l o pera mi de resc ue me dicati o n f or ac ute treat me nt of u nc o ntr olle d diarr hea. T he t otal d urati o n of t he st u d y is u p t o 1 1 wee ks, w hic h i ncl u des: scree ni n g peri o d (0 - 2 wee ks), pr etreat me nt peri o d ( 2 -3 wee ks), 4 -wee k o pe n -la bel treat me nt peri o d, a n d 2-wee k p ost -treat me nt f oll o w-u p peri o d. A t otal of 6 st u d y visits are pla n ne d f or eac h partici pa nt :  Scree ni n g, Wee k -3 t o - 5 ( Visit 1) pri or t o Baseli ne visit  Pretreat me nt, Wee k -3 t o -2 ( Visit 2) pri or t o Baseli ne visit  D a y 1 ( Visit 3; first a d mi nistrati o n of st u d y dr u g)  Wee k 2 ( Visit 4; Wee k 2 of treat me nt), ma y be d o ne b y tele p h o ne  Wee k 4 ( Visit 5; en d of treat me nt/earl y ter mi nati o n)  Wee k 6 ( Visit 6; p ost -treat me nt f oll o w-u p) T he st u d y desi g n is prese nte d i n Ta ble 5 – 1 . T a ble 5 – 1 St u d y Desi g n Peri o d Scree ni n gaPretre at m e ntaO pe n -L a bel Tre at me nt P ost -Tre at m e nt D ur ati o n 0- 2 w ee ks 2- 3 w ee ks 4 w ee ks 2 w ee ks Wee k Scree ni n g Pretreat me nt Baseli ne Wee k 2bWee k 4 ( E O T/ E T)Wee k 6b ( F oll o w-u p) St u d y Visit 1 2 3 4 5 6 St u d y D a y 1 1 5 ( ± 2) 2 9 ( ± 2) Visit 5 + 1 4 da ys (± 7 ) 7 α C 4 = 7a -h y dr o x y - 4-c h oleste n- 3-o ne ; B A = bile aci d aScree ni n g a n d pretreat me nt peri o ds ma y be c o mbi ne d if res ults of fasti n g ser u m 7 α C 4 test or 4 8 -h o ur fecal B A c ollecti o n c o n d ucte d wit hi n 1 cale n dar year fr o m scree ni n g are a vaila ble at t he ti me of t he c o m bi ne d visit or res ults fr o m fasti n g ser u m 7 α C 4 test are a vaila ble pri or t o t he start of st u d y treat me nt. bM a y be d o ne o ver t he p h o ne. 5. 2. P artici p a nt a n d St u d y C o m pleti o n A ma xi m u m of 2 4 partici pa nt s, 1 2 partici pa nt s wit h e vi de nce of B A M a n d 1 2 partici pa nt s wit h o ut e vi de nce of B A M will recei ve st u d y treat me nt s uc h t hat a p pr o xi matel y 2 4 e val ua ble partici pa nt s c o m plete t he st u d y."
23,page_23,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 35. 3. E n d of St u d y Defi niti o n T he e n d of t he st u d y is defi ne d as t he date of Visit 6 ( p ost -treat me nt f oll o w-u p visit). A partici pa nt is c o nsi dere d t o ha ve c o m plete d t he st u d y if he/s he has c o m plete d all peri o d s of t he st u d y i ncl u di n g post -treat me nt f oll o w-u p visit. 5. 4. Scie ntific R ati o n ale f or St u d y Desi g n T his is a n o pe n -la bel, c o h ort c o ntr olle d st u d y desi g ne d t o e val uate t he c o m parati ve effects of el u xa d oli ne o n t he altere d b o wel f u ncti o n i n I B S -D partici pa nts wit h a n d wit h o ut e vi de nce of B A M. T his n o n -ra n d o mize d desi g n is c o nsi dere d m ost a p pr o priate si nce t he c o h ort assi g n me nt will be base d o n t he deter mi nati o n of B A M stat us. A pri mar y fact or i n t he desi g n of t his st u dy is t he mec ha nis m b y w hic h e vi de nce of B A M will be esta blis he d a n d d oc u me nte d i n t he patie nt p o p ulati o n. B ot h t he R o me I V criteria a n d E M A g ui deli ne f or I B S s u g gest t hat t he res ults fr o m a t hera pe utic st u d y wit h a bile aci d bi n di n g a ge nt ca n be a n a p pr o priate s urr o gate gi ve n t hat t hese a ge nts ha v e bee n s h o w n t o i m pr o ve st o ol passa ge a n d st o ol c o nsiste nc y i n patie nts wit h B A M (W o n g 2 0 1 2 ; Baj or 2 0 1 5 ). W hile e m piric st u dies of se q uestra nts s uc h as c h olest yr a mi ne or c olese vela m ha ve t he a d va nta ge of bei n g cli nicall y a p plica ble, t he y pr o vi de o nl y i n direct e vi de nce of B A M si nce t hese a ge nts ca n ha ve n o ns pecific effects t o a meli orate diarr hea of ot her ca uses ( Ca milleri 2 0 1 5 ). A d diti o nall y, t hera pe utic st u dies of c h olest y ra mi ne are ha m pere d b y t olera bilit y a n d c o m plia nce iss ues o wi n g t o its p o or palata bilit y a n d p ote ntial si de effects, w hile st u dies of t he ne wer a ge nt c olese vela m are ha m pere d b y its e x pe nse ( Ca milleri 2 0 1 4 ). M o st p ote ntiall y direct dia g n ostic tests of B A M are li mite d i n t heir a vaila bilit y a n d/ or cli nical practicalit y. T he m ost defi niti ve test is t he meas ure me nt of fecal bile aci ds i n a 4 8 -h o ur st o ol c ollecti o n . Meas ure me nt of fecal bile aci ds is a direct meas ure of e xcess bile aci ds e nteri n g t he c ol o n. Pri mar y fecal bile aci ds [C he n o de o x yc h olic aci d ( C D C A) a n d c h olic aci d ( C A)] are si g nifica ntly hi g her i n patie nts wit h B A M a n d c orrelate wit h st o ol fre q ue nc y a n d c o nsiste nc y (S hi n 2 0 1 3 , W o n g 2 0 1 2 ). A p ote ntial alter nati ve, t he n uclear me dici ne Se H C A T test w hic h meas ures bile aci d rete nti o n is m ore cli nicall y practical b ut d oes re q uire 2 se parate cli nical visits t o deter mi ne Se H C A T rete nti o n after a wee k. W hile Se H C A T testi n g has bee n t he pri mar y meas ure b y w hic h t he o verla p of B A M a n d I B S-D has bee n i de ntifie d, it is n ot a p pr o ve d f or use i n t he U nite d States a n d is n ot wi del y a vaila ble i n t he rest of t he w orl d (Isla m 2 0 1 2 ). T otal fecal bile aci ds > 2 3 3 7 μ m ol/ 4 8 hr is t he g ol d sta n dar d f or B A M dia g n osis i n c o u ntries w here Se H C A T rete nti o n is n ot a vaila ble (S hi n 2 0 1 3 ). T he t y pical pr o p orti o n of pri mar y fecal bile aci ds i n healt h y v ol u nteers is ~ 0. 2 %. Patie nts wit h B A M ha ve hi g her st o ol wei g ht c o m pare d t o t h ose wi t h c hr o nic diarr hea wit h o ut B A M or healt hy v ol u nteers ( Vija y var gi ya 2 0 1 8 ). T he se nsiti vit y a n d s pecificity of t he fecal bi o mar kers of B A M are liste d i n Ta ble 5- 2 . T heref ore, ele vate d pri mar y B A al o ne or i n c o m bi nati o n wit h t otal fecal bile aci ds of ≥ 1 0 0 0 μ m ol/ 4 8 hr ha ve a si milar dia g n ostic acc urac y as t otal fecal B A al o ne of > 2 3 3 7 μ m ol/ 4 8 hr i n det ecti n g ele vate d f ecal wei g ht i n patie nts wit h B A M . Statistical a nal y sis has de m o nstrate d n o si g nifica nt differe nce bet wee n t he R O C c ur ve t o esti mate ele vate d fecal wei g ht f or eit her t otal B A or ele vate d pri mar y fecal B A ( p = 0. 1 3). After i ncreasi n g t he pri ma r y"
24,page_24,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 4B A c ut off t o 1 0 % or hi g her wit h t otal fecal B A ≥ 1 0 0 0 µ m ol/ 4 8 hr , t here was n o si g nifica nt gai n i n eit her se nsiti vit y ( 4 1 %) or s pecificit y ( 9 7 %) c o m pare d t o t he l o wer c ut off of pri mar y B A ≥ 4 % wit h t otal fecal B A ≥ 1, 0 0 0 μ m ol/ 4 8 hr (Vija y var gi ya 2 0 1 8 ). T heref ore, e ve n at t he l o wer c ut off val ues of ≥ 4 %, pri mar y fecal bile aci ds are i n dicati ve of B A D e ve n t h o u g h t he t otal fecal B A ma y be o nl y 1 0 0 0 μ m ol/ 4 8 hr. H o we ver, i n a n a nal y sis of 9 8 6 patie nts w ho u n der we nt 4 8 h o ur fecal B A e val uati o n f or c hr o nic diarr hea, 2 6 % of patie nts ha d ele vate d t otal fecal bile aci ds w hereas 4 6 % of patie nts ha d fecal pri mar y bile aci ds ≥ 1 0 %, i n dicati n g t hat meas uri n g t otal fecal bile aci ds al o ne will miss a s u b gr o u p of patie nts w h o ha ve feat ures of B A M ( Vija y var gi ya 2 0 1 8) . E vi de nce has s u g geste d t hat meas ure me nt of ser u m 7 α- h y dr o x y- 4- c h oleste n - 3-o ne ( 7 αC 4 test) ma y als o be a n effecti ve i n dicat or of B A M. Ser u m 7 α C 4 is a s urr o gate f or he patic B A sy nt hesis rate a n d has bee n dem o nstrate d t o be ele vate d i n patie nts wit h B A M ( E us ufzai 1 9 9 3 ) a n d i n s o me patie nts wit h I B S-D ( O d u nsi -S hi y a n ba de 2 0 1 0 ; W o n g 2 0 1 2 ). T he use of ser u m 7 α C 4 t o dia g n ose B A M has bee n vali date d a gai nst Se H C A T testi n g a n d was de m o nstrate d t o ha ve a p pr o xi matel y 9 0 % se nsiti vit y a n d 7 9 % s pecificit y (Sa uter 1 9 9 9 ). T he fasti n g ( 6 -1 0 a m) ser u m 7 α C 4 test is c o nsi dere d m ost i deal beca use of its si m plicit y, as c ollecti o n of bl o o d f or 7 α C 4 a nal ys is ca n occ ur as part of t he r o uti ne scree ni n g pr ocess f or t he st u d y. T he a nalys is of ser u m 7 α C 4 le vels re q uires a li q ui d c hr o mat o gra p h y- ta n de m mass s pectr o metr y ( L C-M S/ M S) met h o d w hic h is c urre ntl y a vaila ble (Ca milleri 2 0 0 9 ; Ca milleri 2 0 1 4a ). F urt her, ser u m 7 α C 4 was de m o nstrate d t o ha ve hi g h p ositi ve a n d ne gati ve pre dicti ve val ues ma ki n g it attracti ve as a dia g n ostic test of B A M. T heref o re, in t his st u d y , B A M stat us will be deter mi ne d b y t he prese nce of at least o ne of t he para meters liste d i n Ta ble 5- 2 . T he sa m ple size is base d pri maril y o n cli nical c o nsi derati o ns, i ncl u di n g t he desire t o mi ni mize t he n u m ber of p ote ntial cli nical sites gi ve n t he p ossi ble nee d t o utilize a researc h la b orat or y f or a nal ys is of scree ni n g ser u m 7 α C 4 sa m ples. W hile n ot statisticall y p o were d, t he st u d y sa m ple is c o nsi dere d s ufficie nt t o c haracterize t he effects of el u xa d oli ne o n t he altere d b o wel f u ncti o n of I B S-D patie nts wit h B A M a n d t o q ualitati vel y e val uate w het her t hese patie nts res p o n d differe ntl y t o el u xa d oli ne treat me nt. T he d urati o n of treat me nt was c h ose n t o be c o nsiste nt wit h cli nic al practice i n I B S, w here a 1- m o nt h t hera pe utic st u d y of a ne w a ge nt is c o m m o n a n d is s u p p orte d b y res ults of t he P hase 3 st u dies w hic h s h o we d t hat a patie nt’s res p o nse t o el u xa d oli ne treat me nt o ver t he first m o nt h is reas o na bly pre dicti ve of res p o nsi ve ness o ver l o n ger d urati o ns. T he p ost -treat me nt peri o d is i nte n de d t o all o w f or a n off-treat me nt assess me nt of safety. T he st u d y will e nr oll a n I B S-D p o p ulati o n si milar t o t hat e nr olle d i n t he P hase 3 st u dies of el u xa d oli ne. Partici pa nt s will meet t he R o me I V criteria f or I B S -D, w hic h differs fr o m t he R o me III criteria use d i n t he P hase 3 st u dies pri maril y i n eli mi nati n g a b d o mi nal disc o mf ort as a disti nct e ntit y fr o m a b d o mi nal pai n i n t he defi niti o n of I B S -D ( Lac y 2 0 1 6). E vi de nce of B A M will be deter mi ne d b y a scree ni n g ser u m 7 α C 4 val ue ≥ 5 2. 5 n g/ m L, w hic h has pre vi o usl y bee n utilize d as a dia g n ostic c ut off f or B A M base d o n t his val ue bei n g greater t ha n t he 9 5t hperce ntile of ser u m 7 α C 4 val ues fr o m 1 8 4 healt h y c o ntr ols (Vija y var gi ya 2 0 1 7 )."
25,page_25,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 5I n or der t o ha ve c o m para ble treat me nt gr o u ps, t he c o h orts will be matc he d t o t he hi g hest e xte nt p ossi ble b y a ge, ge n der a n d se verity of hist oric s y m pt o ms base d o n t he i n vesti gat or's discreti o n. I m pr o ve me nts i n b o wel s y m pt o ms will be meas ure d d uri n g t he st u d y. St o ol c o nsiste nc y is a hi g hl y se nsiti ve efficac y mar ker, ma ki n g it i deally s uita ble t o detect p ote ntial differe nces i n res p o nsi ve ness t o treat me nt a m o n g partici pa nt s wit h a n d wit h o ut e vi de nce of B A M. T he pri mar y o utc o me meas ure f or t his st u d y will t heref ore be c ha n ges fr o m baseli ne i n st o ol c o nsiste nc y sc ores o ver t he 4-wee k treat me nt peri o d. C ha n ges fr o m baseli ne are c o nsi dere d m ore a p pr o priate t ha n m o nt hl y res p o n der defi niti o ns gi ve n t he s mall pil ot nat ure of t his st u d y. T a ble 5- 2 C urre nt a n d f ut ure a n d bile aci d di arr he a ( B A D) di a g n ostic tests Di a g n ostic Test F asti n g ser u m C 4 T ot al fec al B A Pri m ar y B A > 4 % + t ot al fec al B A Fec al pri m ar y B A > 1 0 % W h at d oes it me as ureHe patic bile aci d s y nt hesisT otal fecal bile aci d e xcrete d fr o m t he c ol o nA m o u nt of bile aci ds wit h secret or y p ote ntial wit h t otal fecal B A e xcreti o nA m o u nt of bile aci ds t hat are directl y s y nt hesize d fr o m t he li ver wit h secret or y p ote ntial Di a g n ostic C ut offs > 5 2. 5 n g/ m L > 2, 3 3 7 μ m ol/ 4 8 hPri mar y B A ≥4 % + t otal fecal B A ≥1, 0 0 0 μ m ol/ 4 8 h≥1 0 % Pri mar y B A Se nsiti vit y rel ati ve t o fec al wei g ht > 4 0 0 g/ 4 8 h1 5 % 5 9 % 4 6 % 4 9 % S pecificit y rel ati ve t o fec al wei g ht > 4 0 0 g/ 4 8 h8 6 % 9 2 % 9 7 % 9 1 % S o urce: Vija y var gi ya 2 0 1 8 5. 5. J ustific ati o n f or D ose T he 1 0 0 m g BI D d ose selecte d f or t his st u d y is c o nsiste nt wit h U S a n d gl o bal la beli n g f or el u xa d oli ne i n IB S -D."
26,page_26,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 66. St u d y P o p ul ati o n Pr os pecti ve a p pr o val of pr ot oc ol de viati o ns t o recr uit me nt a n d e nr oll me nt criteria, als o k n o w n as pr ot oc ol wai vers or e xe m pti o ns, is n ot per mitte d. 6. 1. I ncl usi o n Criteri a Partici pa nts are eli gi ble t o be i ncl u de d i n t he st u d y o nl y if all of t he f oll o wi n g criteria a p pl y: 1. A ge / Se x 1. 0 1 Partici pa nt is a ma n or w o ma n a ge d 1 8 t o 7 5 ye ars, i ncl usi ve, at s cree ni n g. 2. T y pe of P artici p a nt a n d Dise ase C h ar acteristics 2. 0 2 Partici pa n t has a dia g n osis of I B S wit h pre d o mi na nt diarr hea (I B S -D) defi n e d b y t he R o me I V criteria as > ¼ ( 2 5 %) of b o wel m o ve me nts wit h B S F S sc ore of 6 or 7 a n d < ¼ ( 2 5 %) of b o wel m o ve me nts wit h B S F S sc ore of 1 or 2. 2. 0 3 Partici pa nt s wit h e vi de nce of B A M: Partici pa nt s m ust ha ve at least o ne of t he f oll o wi n g at scree ni n g or wit hi n 1 cale n dar year pri or t o scree ni n g.  fasti n g ser u m 7a -h y dr o x y - 4-c h oleste n- 3-o ne ( 7 α C 4) le vel ≥ 5 2. 5 n g/ m L  t otal fecal bile aci ds > 2 3 3 7 micr o m oles/ 4 8 h o urs  pri mar y bile aci ds (fecal C A a n d C D C A) ≥ 1 0 % i n a 4 8 h fecal c ollecti o n  pri mar y bile aci ds (fecal C A a n d C D C A) ≥ 4 % wit h t otal fecal bile aci d ≥ 1, 0 0 0 micr o m oles/ 4 8 hr"
27,page_27,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 72. 0 4 Partici pa nt s wit h o ut B A M: Partici pa nt s m ust ha ve at least o ne of t he f oll o wi n g at scree ni n g or w it hi n 1 cale n dar year pri or t o s cree ni n g.  fasti n g ser u m 7 α C 4 le vel ≤ 4 7. 1 n g/ m L  fasti n g ser u m 7 α C 4 le vels > 4 7. 1 n g/ m L b ut < 5 2. 5 n g/ m L wit h fecal bile aci ds t hat are ne gati ve f or bile aci d mala bs or pti o n (i.e. d o n ot meet criteria 2. 0 3 base d o n fecal b ile aci ds le vel)  t otal fecal bile aci ds ( B A) ≤ 2 3 3 7 micr o m oles/ 4 8 h o urs  pri mar y bile aci ds (fecal C A a n d C D C A) < 1 0 % i n a 4 8 h fecal c ollecti o n  pri mar y bile aci ds (fecal C A a n d C D C A) < 4 % wit h t otal fecal bile aci d < 1, 0 0 0 micr o m oles / 4 8 hr 2. 0 5 Partici pa nt meets t he c ol o n osc o p y re q uire me nts defi ne d i n A p pe n di x 1 0 Secti o n 1 2. 1 0 , w hic h are m o difie d fr o m t he S u m mar y of t he U S-M ulti -S ociet y Tas k F orce o n C ol orectal Ca ncer a n d ot her C ol o n osc o p y Re q uire me nts 2. 0 6 Partici pa nt has a n a vera ge dail y B S F S sc ore ≥ 5. 0 or at l east 2 5 % of da ys of diar y e ntr y wit h a B S F S sc ore of 6 or 7 d uri n g t he 1 4 da y s pri or t o Da y 1 of st u d y treat me nt 3 . C o ntr ace pti ves 3. 0 1 A se x uall y acti ve w o ma n of c hil d beari n g p ote ntial ( W O C B P), as defi ne d i n A p pe n di x 5, Secti o n 1 2. 5 m ust a gree t o f oll o w t he c o ntrace pti ve g ui da nce gi ve n i n A p pe n di x 5, Secti o n 1 2. 5 fr o m t he date s he pr o vi de s i nf or me d c onse nt u ntil 2 4 h o urs after her fi nal d ose of st u d y dr u g. 4 . I nf or me d C o nse nt 4 . 0 1 Partici pa nt m ust si g n a n i nf or me d c o nse nt f or m (I C F) bef ore t he i nitiati o n of a n y st u d y-relate d pr oce d ures i n dicati n g t hat he or s he u n dersta n ds t he p ur p ose of a n d pr oce d ures re q uire d f or t he st u d y a n d is willi n g t o partici pate i n t he st u d y. 5 . Ot her 5 . 0 1 Partici pa nt has c o m plete d t he e D iar y o n at least 1 0 of t he 1 4 da ys pri or t o Da y 1 of st u d y treat me nt. 5 . 0 2 Partici pa nt has n ot use d l o pera mi de resc ue me dicati o n o n m ore t ha n 3 da y s i n t he 1 4 da y s pri or t o Da y 1 of st u d y treat me nt (see Secti o n 7. 7. 3 )."
28,page_28,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 86. 2. E xcl usi o n Criteri a Partici pa nts are e xcl u de d fr o m t he st u d y if a n y of t he f oll o wi n g criteria a p pl y: 1. Me dic al C o n diti o ns 1. 0 1 Partici pa nt has a dia g n osis of I B S wit h a s u bt y pe of I B S wit h c o nsti pati o n , mi xe d I B S, or u ns u bt y pe d I B S b y t he R o me I V criteria. 1. 0 2 Partici pa nt d oes n ot ha ve a gall bla d der. 1. 0 3 Partici pa nt s wit h k n o w n or s us pecte d biliar y d uct o bstr ucti o n, or s p hi ncter of O d di disease or d ys f u ncti o n. Partici pa nt s wit h a hist or y of gallst o nes ma y be e nr olle d. 1. 0 4 Partici pa nt has a hist or y of alc o h olis m, alc o h ol a b use or alc o h ol a d dicti o n, or dri n ks m ore t h a n 3 alc o h olic be vera ges per da y. 1. 0 5 Partici pa nt has a hist or y of pa ncreatitis; str uct ural diseases of t he pa ncreas, i ncl u di n g k n o w n or s us pecte d pa ncreatic d uct o bstr ucti o n. 1. 0 9 Partici pa nt has d oc u me nte d hist or y of mil d, m o derate, or se vere he patic i m pair me nt acc or di n g t o C hil d -P u g h classificati o n."
29,page_29,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 2 91. 1 0 Partici pa nt has a hist or y or c urre nt dia g n osis of i nfla m mat or y or i m m u ne- me diate d GI dis or ders i ncl u di n g i nfla m mat or y b o wel disease (ie, Cr o h n’s disease, ulcerati ve c olitis, micr osc o pic c olitis). 1. 1 3 Partici pa nt has celiac disease or a p ositi ve ser ol o gical test f or celiac disease, a n d t he c o n diti o n has n ot bee n r ule d o ut b y e n d osc o pic bi o ps y. 1. 1 5 Partici pa nt has a hist or y of a micr o bi ol o gically d oc u me nte d (ie, st o ol c ult ure or me dical hist or y ) GI i nfecti o n wit hi n 3 m o nt hs pri or t o scree ni n g. 2. Pri or/ C o nc o mit a nt T her a p y 2. 0 1 Partici pa nt use d a pr ot oc ol -s pecifie d pr o hi bite d me dicati o n or faile d t o meet t he sta ble - d ose re q uire me nts of certai n me dicati o ns (see Secti o n 7. 7. 1 ) 2. 0 2 Partici pa nt has pre vi o usl y recei ve d el u xa d oli ne. 4 . Ot her 4 . 0 1 Fe male partici pa nt s w h o are c urre ntly pre g na nt or n ursi n g, or pla n t o bec o me pre g na nt or n urse d uri n g t he cli nical st u d y ."
30,page_30,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 04 . 0 2 Partici pa nt has k n o w n aller gies or h y perse nsiti vit y t o o pi oi ds. Na usea a n d v o miti n g i n res p o nse t o o pi oi d treat me nt are n ot hy perse nsiti vit y reacti o ns. Partici pa nt s w h o ha ve ha d pri or mil d, o pi oi d -i n d uce d pr urit us i n t he a bse nce of de m o nstra ble aller gic der matitis, a n gi oe de ma, a n d lar yn geal e de ma are eli gi ble f or t he st u d y . R ati o n ale f or I ncl usi o n a n d E xcl usi o n Criteri a T he eli gi bilit y criteria defi ne d i n t he pr ot oc ol are i nte n de d t o e ns ure e nr oll me nt of a n I B S-D partici pa nt p o p ulati o n c o nsiste nt wit h t he a p pr o ve d gl o bal la beli n g of el u xa d oli ne as well as all o wi n g f or t he selecti ve i ncl usi o n of partici pa nts wit h o verla p pi n g B A M base d o n sta n dar d dia g n ostic met h o d ol o g y . T he eli gi bilit y criteria a n d s pecific dia g n ostic scree ni n g pr oce d ures are i nte n de d t o e xcl u de ot her p ote ntial eti ol o gies of t he partici pa n t’s I B S-D s y m pt o ms a n d, c o nsiste nt wit h gl o bal la beli n g, t o e xcl u de p artici pa n ts w h o ma y be at i ncrease d ris k of e x perie nci n g certai n A Es ass ociate d wit h el u xa d oli ne, s uc h as c o nsti pati o n, S O s pas m, or pa ncreatitis. T he i ncl usi o n criteria relate d t o e Diar y e ntries are i nte n de d t o e ns ure partici pa nt s ha ve s ufficie nt baseli ne diar y data a n d diarr heal sy m pt o ms of a s ufficie nt i nte nsit y t o detect a treat me nt differe nce wit h el u xa d oli ne. 6. 3. Lifest yle Restricti o ns N o lifest y le restricti o ns are re q uire d. 6. 4. Scree n F ail ures Scree n fail ures are defi ne d as partici pa nt s w h o c o nse nt t o partici pate i n t he cli nical st u d y b ut are n ot s u bse q ue ntl y e ntere d i n t he st u d y t o recei ve st u d y treat me nt. A mi ni mal set of scree n fail ure i nf or mati o n is re q uire d t o e ns ure tra ns pare nt re p orti n g of scree n fail ure partici pa nt s t o meet t he C o ns oli date d Sta n dar ds of Re p orti n g Trials ( C O N S O R T) p u blis hi n g re q uire me nts a n d t o res p o n d t o q ueries fr o m re g ulat or y a ut h orities. Mi ni mal i nf or mati o n i ncl u des de m o gra p hy, scree n fail ure details, eli gi bilit y criteria, a n d a ny seri o us a d verse e ve nt ( S A E)."
31,page_31,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 1I n di vi d uals w h o d o n ot meet t he criteria f or partici pati o n i n t his st u d y (scree n fail ures) m a y b e rescree ne d.
32,page_32,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 27. Tre at me nt s St u d y treat me nt is defi ne d as a ny i n vesti gati o nal treat me nt(s), mar kete d pr o d uct(s), place b o, or me dical de vice (s) i nte n de d t o be a d mi nistere d t o a st u d y partici pa nt acc or di n g t o t he st u d y pr ot oc ol. 7. 1. Tre at me nt s A d mi nistere d T a ble 7 – 1 Tre at m e nts A d mi nistere d St u d y Tre at me nt N a me El u xa d oli ne D os a ge F or m ul ati o n fil m-c oate d ta blet U nit D ose Stre n gt h(s)/ D os a ge Le vel(s)1 0 0 m g BI D R o ute of A d m i nistr ati o n Oral D osi n g I nstr ucti o ns O ne ta blet t wice a da y t o be ta ke n wit h f o o d M a n uf act urer Aller ga n 7. 2. D ose M o dific ati o n N o d ose m o dificati o n will be all o we d . Retre at me nt Criteri a N o retreat me nt will be all o we d . 7. 3. Met h o d of Tre at me nt Assi g n me nt T his is a n o pe n -label, parallel -gr o u p st u d y . El u xa d oli ne 1 0 0 m g BI D will be a d mi nistere d t o all partici pa nt s i n t he st u d y after t he y are q ualifie d base d o n meeti n g all eli gi bilit y criteria. Partici pa nt s will be stratifie d i nt o 2 c o h orts: I B S -D partici pa nts wit h e vi de nce of B A M a n d I B S-D partici pa nt s wit h o ut e vi de nce of B A M. As far as p ossi ble, t he 2 c o h orts will be matc he d b y a ge, ge n der a n d se verit y of hist oric s y m pt o ms base d o n t he i n vesti gat or's discreti o n. St u d y partici pa nts w h o ha ve disc o nti n ue d t he st u d y ma y n ot be re place d."
33,page_33,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 37. 4. Bli n di n g/ M as ki n g O pe n -l a bel, N o Bli n di n g at Site Le velT his is a n o pe n -la bel st u d y; p ote ntial bias will be re d uce d b y t he f oll o wi n g ste ps: matc hi n g n o n -B A M partici pa nt s t o B A M partici pa nts b y eli gi bilit y criteria f ulfilled d uri n g baseli ne peri o d 7. 5. Pre p ar ati o n/ H a n dli n g/ St or a ge/ Acc o u nt a bilit y T he i n vesti gat o r or desi g nee m ust c o nfir m a p pr o priate te m perat ure c o n diti o ns ha ve bee n mai ntai ne d d uri n g tra nsit f or all st u d y treat me nt recei ve d a n d a n y discre pa ncies are re p orte d a n d res ol ve d bef ore use of t he st u d y treat me nt. 1. O nl y partici pa nt s e nr olle d i n t he st u d y may recei ve st u d y treat me nt , a n d o nl y a ut h orize d site staff ma y s u p ply or a d mi nister st u d y treat me nt. 7. 6. Tre at me nt C o m pli a nce Treat me nt c o m plia nce will be assesse d at t he st u d y site b y pill c o u nts. T his re vie w will be d oc u me nte d i n t he s o urce d oc u me nts. 7. 7. C o nc o mit a nt T her a p y All prescri pti o n dr u gs, her bal pr o d ucts, vita mi ns, mi nerals, a n d o ver -t he-c o u nter me dicati o ns ta ke n wit h i n 3 0 d a y s pri or t o t he o pe n-la bel treat me nt peri o d will be rec or de d as pri or me dicati o ns. It will als o be deter mi ne d w hic h pri or me dicati o ns were prescri be d or ta ke n o ver -t he-c o u nter b y p artici pa nts f or t he treat me nt of I B S -D."
34,page_34,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 4All me dicati o ns ta ke n after be gi n ni n g o pe n -la bel treat me nt a n d t hr o u g h t he early ter mi nati o n or f oll o w-u p visit will be rec or de d as c o nc o mita nt t hera p y. T he u se of all pri or a n d c o nc o mita nt me dicati o ns is t o be rec or de d o n t he partici pa nt ’s electr o nic case re p ort f or m (e C R F) at eac h visit al o n g wit h t he reas o n t he me dicati o n wa s ta ke n. A n y c ha n ges i n c o nc o mita nt me dicati o ns will als o be rec or de d o n t he partici pa n t’s e C R F. T he mi ni m u m re q uire me nt is t hat dr u g na me a n d t he dates of a d mi nistrati o n are t o be rec or de d. A n y c o nc o mita nt me dicati o n dee me d necessary f or t he welfare of t he partici pa nt d uri n g t he st u d y ma y be gi ve n at t he discreti o n of t he i n vesti gat or. H o we ver, it is t he res p o nsi bilit y of t he i n vesti gat or t o e ns ure t hat details re gar di n g t he me dicati o n are rec or de d i n full i n t he s o urce d oc u me nts as well as i n t he e C R F. 7. 7. 1. Pr o hi bite d Tre at me nts Bef ore a n d D uri n g t he St u d y Partici pa nts m ust disc o nti n ue a n y of t he me dicati o ns liste d i n t he ta ble bel o w f or t he s pecifie d peri o d pri or t o D a y 1. T hese me dicati o ns are pr o hi bite d for t he d urati o n of t he st u d y . Ot her me dicati o ns bei n g use d at scree ni n g ma y be c o nti n ue d. 7. 7. 2. Per mitte d Tre at me nts A n y me dicati o n or vacci ne (i ncl u di n g o ver-t he-c o u nter or prescri pti o n me dici nes, vita mi ns , a n d/ or her bal s u p ple me nts) t hat t he partici pa nt is recei vi n g at t he ti me of e nr oll me nt or recei ves d uri n g t he st u d y m ust be rec or de d al o n g wit h :  I n dicati o n  D ates of a d mi nistrati o n i ncl u di n g start a n d e n d dates  D osa ge i nf or mati o n i ncl u di n g d ose a n d fre q ue nc y"
35,page_35,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 5T hera p y c o nsi dere d necessar y f or t he partici pa nt’s welfare ma y be gi ve n at t he discreti o n of t he i n vesti gat or. If t he per missi bilit y of a s pecific me dicati o n/treat me nt is i n q uesti o n, please c o ntact t he s p o ns or. T he s p o ns or or desi g nee s h o ul d be c o ntacte d if t here are a ny q uesti o ns re gar di n g c o nc o mita nt or pri or t hera p y. 7. 7. 3. Resc ue Me dici ne L o pera mi de h y dr oc hl ori de ma y be use d as resc ue me dicati o n f or ac ute treat me nt of diarr hea d uri n g t he pretreat me nt a n d o pe n -la bel treat me nt peri o ds. L o pera mi de resc ue me dicati o n use will be rec or de d b y t he partici pa nt i n t he e Diar y."
36,page_36,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 67. 8. Tre at me nt a fter t he E n d of t he St u d y N ot a p plica ble .
37,page_37,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 78. Disc o nti n u ati o n/ Wit h dr a w al Criteri a Pre mat ure disc o nti n uati o n of t he st u d y will occ ur w he n a partici pa nt ceases partici pati o n i n t he st u d y, re gar dless of circ u msta nces, bef ore t he c o m pleti o n of t he st u d y visits a n d pr oce d ures. N otificati o n of earl y partici pa nt disc o nti n uati o n fr o m t he st u d y a n d t he reas o n f or st u d y disc o nti n uati o n will be se nt t o t he s p o ns or a n d will be clearl y d oc u me nte d o n t he e C R F. Reas o ns f or pre mat ure disc o nti n uati o n fr o m t he st u d y treat me nt a n d/ or t he st u d y ma y i ncl u de t he f oll o wi n g:  A d verse e ve nt  Deat h  Lac k of efficac y  L ost t o f oll o w -u p  N o n- c o m plia nce wit h st u d y dr u g  Ot her  P h y sicia n de cisi o n  Pre g na nc y  Pr ot oc ol de viati o n  Site ter mi nate d b y s p o ns or  Wit h dra wal b y s u bject W he n a partici pa nt disc o nti n ues st u d y treat me nt, t he reas o n(s) f or treat me nt disc o nti n uati o n s hall be rec or de d b y t he i n vesti gat or o n t he rele va nt pa ge of t he e C R F. W he ne v er p ossi ble, all e nr olle d pa rtici pa nts w h o pre mat urely disc o nti n ue st u d y treat me nt will u n der g o al l E O T/ E T visit assess me nts. It is vital t o o btai n f oll o w-u p data o n a n y p artici pa nt disc o nti n ui n g st u d y treat me nt beca use of a n A E or S A E . I n e ver y case, eff orts m ust be ma de t o u n derta ke pr ot oc ol -s pecifie d safet y f oll o w-u p pr oce d ures u ntil res ol uti o n or sta bilizati o n. 8. 1. Disc o nti n u ati o n of St u d y Tre at me nt Partici pa nts m ust pre mat urel y disc o nti n ue st u d y treat me nt f or reas o ns of safet y i ncl u di n g:  a n S A E c o nsi de re d b y t he i n vesti gat or or t he sp o ns or t o be p ossi bl y relate d or relate d t o i n vesti gati o nal pr o d uct,  a n A E of s pe cial i nterest ( S O s pas m, pa ncreatitis, se vere c o nsti pati o n) see Secti o n 9. 2. 8. 1 ,  pre g na nc y , see Secti o n 9. 2. 7 ,"
38,page_38,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 8 si g ns of dr u g-i n d uce d li ver i nj ur y ( DI LI), see A p pe n di x 6, Secti o n 1 2. 6 . Partici pa nt s ma y pre mat urel y disc o nti n ue st u d y treat me nt f or reas o ns of safet y i ncl u di n g:  t he prese nce of i nte nti o nal o ver d ose or i nte nti o nal mis use per i n vesti gat or discreti o n,  a n A E i n dicati ve of a ce ntral ner v o us s ys te m (C N S ) o pi oi d effect, e g, pi n p oi nt p u pils, l oss of c o nsci o us ness, deliri u m, se dati o n or s o m n ole nce, e u p h oric, a n xi o us or de presse d m o o d, t hat i n t he o pi ni o n of t he i n vesti gat or or t he sp o ns or is p ossi bl y relate d or relate d t o t he i n vesti gati o nal pr o d uct,  a vital si g n, a n d/ or la b orat or y a b n or malit y j u d ge d t o be cli nicall y si g nifica nt b y t he in vesti gat or a n d t hat i n t he o pi n i o n of t he in vesti gat or or t he s p o ns or is p ossi bl y relate d or relate d t o t he i n vesti gati o nal pr o d uct,  a n i nt olera ble A E ( defi ne d as a n A E t hat s u bjecti vel y w o ul d ca use a partici pa nt t o c o nsi der st u d y wit h dra wal),  a n a bse nce of b o wel m o ve me nts f or ≥ 3 c o nsec uti ve da y s, see Secti o n 9. 2. 8. 1 , base d o n res p o nses rec or de d via e Diar y.  t he use of a n e xcessi ve a m o u nt of l o pera mi de resc ue me dicati o n see Secti o n 7. 7. 3 .  t he occ urre nce of a n y ot her A E t hat i n t he o pi n i o n of t he in vesti gat or or t he s p o ns or is p ossi bl y relate d or relate d t o t he st u d y treat me nt t hat re prese nts a cli nically si g ni fica nt safety ris k t o t he partici pa nt. See t he sc he d ule of acti vities (Secti o n 2 ) f or data t o be c ollecte d at t he ti me of treat me nt disc o nti n uati o n a n d f oll o w -u p a n d f or a n y f urt her e val uati o ns t hat nee d t o be c o m plete d . 8. 1. 1. Te m p or ar y Disc o nti n u ati o n Te m p orar y disc o nti n uati o ns are n ot all o we d. 8. 1. 2. Rec h alle n ge Rec halle n ge is n ot all o we d . 8. 2. Wit h dr a w al fr o m t he St u d y 1. A partici pa nt m a y wit h dra w fr o m t he st u dy at a n y ti me at his/ her o w n re q uest, or ma y be wit h dra w n at a n y ti me at t he discreti o n of t he i n vesti gat or f or safet y, be ha vi oral, c o m plia nce, or a d mi nistrati ve reas o ns . 2. If t he partici pa nt wit h dra ws c o nse nt f or discl osure of f ut ure i nf or mati o n, t he s p o ns or ma y retai n a n d c o nti n ue t o use a ny data c ollecte d bef ore s uc h a wit h dra wal of c o nse nt . 3. If a partici pa nt wit h dra ws fr o m t he st u d y , he/s he ma y re q uest destr ucti o n of a ny sa m ples ta ke n a n d n ot teste d, a n d t he i n vesti gat or m ust d oc u me nt t his i n t he site st u d y rec or ds. 4. See t he S o A f or data t o be c ollecte d at t he ti me of st u d y disc o nti n uati o n a n d f oll o w -u p a n d f or a ny f urt her e val uati o ns t hat nee d t o be c o m plete d ."
39,page_39,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 3 98. 3. L ost t o F oll o w U p A partici pa nt will be c o nsi dere d l ost t o f oll o w -u p if he or s he re peate dl y fails t o ret ur n f or sc he d ule d visits a n d is u na ble t o be c o ntacte d by t he st u d y site.
40,page_40,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 09. St u d y Assess me nts a n d Pr oce d ures  St u d y pr oce d ures a n d t heir ti mi n g are s u m marize d i n t he S o A.  Pr ot oc ol wai ver s or e xe m pti o ns are n ot all o we d.  I m me diate safet y c o ncer ns s h o ul d be disc usse d wit h t he s p o ns or i m me diatel y u p o n occ urre nce or a ware ness t o deter mi ne if t he partici pa nt s h o ul d c o nti n ue or disc o nti n ue st u d y treat me nt.  A d here nce t o t he st u d y d esi g n re q uire me nts, i ncl u di n g t h ose s pecifie d i n t he S o A , is esse ntial a n d re q uire d f or st u d y c o n d uct.  All scree ni n g e val uati o ns m ust be c o m plete d a n d re vie we d t o c o nfir m t hat p ote ntial partici pa nt s meet all eli gi bilit y criteria. T he i n vesti gat or will mai ntai n a scree ni n g l o g t o rec or d details of all partici pa nt s scree ne d a n d t o c o nfir m eli gi bilit y or rec or d reas o ns f or scree ni n g fail ure, as a p plica ble.  Pr oce d ures c o n d ucte d as part of t he partici pa nt’s r o uti ne cli nical ma na ge me nt (e g, bl o o d c o u nt) a n d o btai ne d bef ore si g ni n g of t he I C F ma y be utilize d f or scree ni n g or baseli ne p u r p oses pr o vi de d t he pr oce d ures met t he pr ot oc ol-s pecifie d criteria a n d were perf or me d wit hi n t he ti me fra me defi ne d i n t he S o A . Scree ni n g (Visit 1 ) Partici pa nt s will u n der g o a scree ni n g visit t o deter mi ne eli gi bilit y t o pr ocee d i n t he st u d y. T his visit ma y be c o m bi ne d wit h t he p retreat me nt v isit if res ults fr o m a fasti n g ser u m 7 α C 4 test or 4 8 -h o ur fecal B A c ollecti o n, c o n d ucte d wit hi n 1 cale n dar ye ar pri or t o scree ni n g, are a vaila ble at t he ti me of t he c o m bi ne d visit or res ults fr o m fasti n g se r u m 7 α C 4 test are a vaila ble pri or t o t he start of st u d y treat me nt. T he scree ni n g visit will occ ur a p pr o xi matel y 2 t o 3 wee ks bef ore t he first d ose of st u d y dr u g (if c o m bi ne d wit h pretreat me nt visit) a n d n o m ore t ha n 5 wee ks bef ore t he first d ose of st u dy d r u g, if t he partici pa nt re q uires a n a d diti o nal wee k f or eac h (scree ni n g a n d pretreat me nt pr oce d ures). Bef ore u n der g oi n g s cree ni n g pr oce d ures, all p ote ntial partici pa nt s will be i nf or me d of t heir pri vac y ri g hts a n d will si g n a n I CF. Partici pa nt s will ha ve t he o p p ort u nit y t o ha ve a ny q uesti o ns a ns were d bef ore si g ni n g t he IC F. T he i n vesti gat or m ust a d dress all q uesti o ns raise d b y t he partici pa nt . T he i n vesti gat or will als o si g n t he I C F. After si g ni n g t he I C F, t he partici pa nt will u n der g o t he scree ni n g assess m e nts a n d pr oce d ures list e d i n t he S o A , i ncl u di n g fasti n g ser u m 7 α C 4 testi n g (if necessar y) a n d cli nical la b orat or y testi n g (ser u m c he mistr y, he mat ol o g y), t o deter mi ne eli gi bilit y . T he i ncl usi o n a n d e xcl usi o n criteria re q uire me nts will be verifie d f or t he partici pa nt . Co nc o mita nt me dicati o n a n d me dical hist or y , i ncl u di n g hist or y s pecifically relate d t o I B S-D, vital si g ns a n d wei g ht will be rec or de d a n d a p h y sical e xa mi nati o n will be perf or me d. Hei g ht will be meas ure d o nl y at scree ni n g."
41,page_41,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 1A ser u m pre g na nc y test will als o be perf or me d f or all w o me n u nless t he y are s ur gically sterile or t here is a d oc u me nte d hist or y of t heir p ost me n o pa usal stat us. If t he pre g na nc y test is p ositi ve, t he partici pa nt is n ot eli gi ble t o e nter t he st u dy. Eli gi ble partici pa nt s will be i nstr ucte d t o ret ur n t o t he st u d y site i n 1 t o 2 wee ks f or t he pre treat me nt visit. Pretre at me nt ( Visit 2 ) T his visit ma y be c o m bi ne d wit h t he scree ni n g visit if res ults fr o m a fasti n g ser u m 7 α C 4 test or 4 8 -h o ur fecal B A c ollecti o n, c o n d ucte d wit hi n 1 cal e n dar ye ar pri or t o scree ni n g, are a vaila ble at t he ti me of t he c o m bi ne d visit or res ults fr o m fasti n g ser u m 7 α C 4 test are a vaila ble pri or t o t he start of st u d y treat me nt. After scree ni n g pr oce d ures ha ve bee n perf or me d, eli gi ble partici pa nt s will e nter t he pre treat me nt peri o d. Partici pa nt s will u n der g o t he p retreat me nt v isit a n d p r oce d ures liste d i n t he S o A. T he p retreat me nt v isit will occ ur a p pr o xi matel y 2 t o 3 wee ks bef o re t he first d ose of st u d y dr u g. T he i ncl usi o n a n d e xcl usi o n criteria, me dical hist or y, c o nc o mita nt me dicati o ns, a n d A Es will be re vie we d, vital si g ns a n d wei g ht will be meas ure d a n d rec or de d. Partici pa nt s will recei ve i nstr ucti o ns o n t he use of resc ue l o pera mi de. Partici pa nt s will be pr o vi de d wit h t he e Diar y de vice a n d i nstr ucte d o n t he use of t he e Diar y s yste m t o rec or d t heir I B S-D s y m pt o ms a n d i nf or mati o n relate d t o t heir b o wel f u ncti o ni n g (e g, b o wel m o ve me nt fre q ue nc y , ur ge nc y a n d e pis o des of i nc o nti ne nce) o n a dail y basis. A d diti o nall y, partici pa nt s will be i nstr ucte d t o rec or d i n t he e Diar y t heir use of l o pera mi de resc ue me dicati o n f or t he ac ute treat me nt of u nc o ntr olle d diarr hea. Partici pa nt s will be eli gi ble f or partici pati o n i n t he st u d y t o recei ve a n o pe n-la bel st u d y treat me nt if t he y meet all 3 of t he f oll o wi n g re q uire me nts:  C o m plia nt i n c o m pleti n g t he e Diar y o n at least 1 0 of t he 1 4 da y s i m me diatel y pri or t o e nr oll me nt i nt o o pe n-la bel treat me nt peri o d of t he st u d y ; a n d  Ha ve a n a vera ge dail y B S F S sc ore ≥ 5 . 0 or at least 2 5 % of d a y s of diar y e ntr y wit h a B S F S sc ore of 6 or 7 d uri n g t he 1 4 da y s pri or t o Da y 1 of st u d y treat me nt, a n d  T he use of resc ue me dicati o n o n n o m ore t ha n 3 da ys d uri n g t he 1 4 da ys pri or t o e nr oll me nt i n t he o pe n -la bel treat me nt peri o d as detaile d i n Secti o n 7. 7. 3 ."
42,page_42,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 2B aseli ne D ay 1 ( Visit 3) O n Da y 1, partici pa nt s w h o were dee me d eli gi ble d uri n g t he pretreat me nt peri o d will be dis pe nse d st u d y treat me nt (el u xa d oli ne 1 0 0 m g BI D). O pe n -L a bel Tre at me nt Peri o d D uri n g t he treat me nt peri o d, partici pa nt s will u n der g o t he assess me nts a n d pr oce d ures liste d i n t he S o A."
43,page_43,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 3Wee k 2 ( Visit 4) Partici pa nt s will ret ur n t o t he st u d y site at Wee k 2 ( ± 2 da ys) of t he st u d y treat me nt. E n d -of -Tre at me nt/ E arly Ter mi n ati o n ( Visit 5) Partici pa nt s will ret ur n t o t he st u d y site at Wee k 4 ( ± 2 da ys) after t he c o m pleti o n of t he treat me nt peri o d. P ost -tre at me nt (Visit 6) T o e ns ure partici pa nt safet y, a ma n dat or y p ost-treat me nt visit will be perf or me d 1 4 da ys after t he last d ose of st u d y dr u g f or partici pa nts t hat c o m plete t he o pe n -la bel treat me nt peri o d. 9. 1. Effic ac y Assess me nts T he efficac y of el u xa d oli ne will be base d o n e Diar y meas ures relate d t o i m pr o ve me nts i n I B S-D si g ns a n d sy m pt o ms. Partici pa nt s will be re q uire d t o access t he e Di ar y eac h e ve ni n g, prefera bl y at t he sa me ti me eac h da y, t o rec or d dail y I B S s y m pt o ms. At t he start of t he pre treat me nt peri o d, partici pa nt s will recei ve f ull trai ni n g i n t he use a n d c o m pleti o n of t he dail y e Diar y."
44,page_44,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 49. 1. 1. D ail y I B S S y m pt o ms Partici pa nts will rec or d t he f oll o wi n g I B S-D si g ns a n d s y m pt o ms d uri n g t heir dail y e Diar y e ntr y d uri n g t he pretreat me nt peri o d a n d t hr o u g h o ut t he 4 wee ks of t he o pe n-la bel treat me nt peri o d:  St o ol C o nsiste nc y : P artici pa nt s will be as ke d t o use t he B S F S t o rate t heir st o ol c o nsiste nc y m ost re prese ntati ve of t he past 2 4 h o urs. T he partici pa nt -re p orte d B S F S is a 1 t o 7 scale w here 1 c orres p o n ds t o a har d st o ol a n d 7 c orres p o n ds t o water y st o ol (A p pe n di x 1 1 , Secti o n 1 2. 1 1 ; O' D o n nell 1 9 8 8 ): 1 = Se parate har d l u m ps li ke n uts ( diffic ult t o pass) 2 = Sa usa ge s ha pe d b ut l u m p y 3 = L i ke a sa usa ge b ut wit h crac ks o n s urface 4 = L i ke a sa usa ge or s na ke, s m o ot h a n d s oft 5 = S oft bl o bs wit h clear -c ut e d ges ( passe d easil y) 6 = Fl uff y pieces wit h ra g ge d e d ges, a m us hy st o ol 7 = Water y , n o s oli d pieces (e ntirely li q ui d)  W orst A b d o mi nal Pai n: P artici pa nt s will be as ke d t o rate t heir w orst a b d o mi nal pai n i n t he past 2 4 h o urs. T he partici pa nt -re p orte d w orst a b d o mi nal pai n i n t he past 2 4 h o urs will be rec or de d o n a 0 t o 1 0 scale, w here 0 c orres p o n ds t o n o pai n a n d 1 0 c orres p o n ds t o w orst i ma gi na ble pai n.  A b d o mi nal Bl oati n g: P artici pa nt s will be as ke d t o rate t heir a b d o mi nal bl oati n g i n t he past 2 4 h o urs. T he partici pa nt -re p orte d w orst a b d o mi nal bl oati n g i n t he past 2 4 h o urs will be rec or de d o n a 0 t o 1 0 scale, w here 0 c orres p o n ds t o n o bl oati n g a n d 1 0 c orres p o n ds t o w orst i ma gi na ble bl oat i n g.  Fre q ue nc y , Ur ge nc y a n d I nc o nti ne nce: P artici pa nt s will be as ke d t o rec ord t he n u m ber of b o wel m o ve me nts, n u m ber of ur ge nt b o wel m o ve me nts, a n d n u m ber of e pis o des of fecal i nc o nti ne nce, o ver t he past 2 4 h o urs. 9. 1. 2. Irrit a ble B o wel S y n dr o me -Q u alit y of Life Q uesti o n n aire T he i m pact of I B S o n partici pa nts’ q ualit y of life will be assesse d usi n g t he I B S- Q ualit y of Life (I B S-Q o L) q uesti o n naire (Dr oss ma n 2 0 0 0 ; Patric k 1 9 9 8 ; A p pe n di x 1 2 , Secti o n 1 2. 1 2 ). T he I B S-Q o L q uesti o n naire will be c o m plete d b y partici pa nts at t he st u d y site at Baseli ne ( Da y 1) pri or t o t he a d mi nistrati o n of st u d y dr u g, a n d Wee k 4 ( or E T visit). T he q uesti o n naire will be c o m plete d at t he be gi n ni n g of t he a p plica ble st u d y visits bef ore all ot her e val uati o ns, es pecially disc ussi o n of A Es or t he partici pa nt ’s me dical c o n diti o n."
45,page_45,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 59. 2. A d verse E ve nts T he defi niti o ns of a n A E or S A E ca n be f o u n d i n A p pe n di x 4 , Secti o n 1 2. 4 . A E s will be re p orte d by t he partici pa nt ( or, w he n a p pr o priate, by a care gi ver, s urr o gate, or t he partici pa nt’ s le gally a ut h orize d re prese ntati ve). T he i n vesti gat or a n d a ny desi g nees are res p o nsi ble f or detecti n g, d oc u me nti n g, a n d rec or di n g e ve nts t hat meet t he defi niti o n of a n A E or S A E a n d re mai n res p o nsi ble f or f oll o wi n g u p A Es t hat are seri o us, c o nsi dere d relate d t o t he st u dy treat me nt or st u d y pr oce d ures , or t hat ca use d t he partici pa nt t o disc o nti n ue t he st u d y (see Secti o n 8 ). 9. 2. 1. Ti me P eri o d a n d Fre q ue nc y f or C ollecti n g A E a n d S A E Inf or m ati o n All A E s/ S A Es fr o m t he start of treat me nt u ntil t he f oll o w-u p visit will be c ollecte d at t he ti mep oi nts s pecifie d i n t he S o A (Secti o n 2 ), a n d as o bser ve d or re p orte d s p o nta ne o usl y by st u d y partici pa nts . A n y cli nicall y si g nifica nt a b n or malities persisti n g at t he e n d of t he st u d y will be f oll o we d u ntil t he A E has res ol ve d. Me di cal occ urre nces t hat be gi n bef ore t he start of st u d y treat me nt b ut after o btai ni n g i nf or me d c o nse nt will be rec or de d o n t he Me dical Hist or y / C urre nt Me dical C o n diti o ns secti o n of t he eC R F , n ot t he A E secti o n. All S A E s will be rec or de d a n d re p orte d t o t he sp o ns or or desi g nee wit hi n 2 4 h o urs, as i n dicate d i n A p pe n di x 4, Secti o n 1 2. 4 . T he i n vesti gat or will s u b mit a n y u p date d S A E data t o t he sp o ns or wit hi n 2 4 h o urs of it bei n g a vaila ble. I n vesti gat ors are n ot o bli gate d t o acti vely see k A E or S A E i nf or mati o n i n f or mer st u dy partici pa nt s. H o we ver, if t he i n vesti gat or lear ns of a n y S A E, i ncl u di n g a deat h, at a n y ti me after a partici pa nt has bee n disc har ge d fr o m t he st u d y, a n d he/s he c o nsi ders t he e ve nt t o be reas o na bl y relate d t o t he st u dy treat me nt or st u d y par tici pati o n, t he i n vesti gat or m ust pr o m ptl y n otif y t he sp o ns or . T he met h o d of rec or di n g, e val uati n g , a n d assessi n g ca usalit y of A Es a n d S A E s a n d t he pr oce d ures f or c o m pleti n g a n d tra ns mitti n g S A E re p orts are pr o vi de d i n A p pe n di x 4 , Secti o n 1 2. 4 . 9. 2. 2. Met h o d of Detecti n g A E s a n d S A E s Care will be ta ke n n ot t o i ntr o d uce bias w he n detecti n g A E s a n d/ or S A Es. O pe n-e n de d a n d n o n -lea di n g ver bal q uesti o ni n g of t he partici pa nt is t he preferre d met h o d t o i n q uire a b o ut A E occ urre nce s."
46,page_46,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 69. 2. 3. F oll o w -u p of A E s a n d S A E s After t he i nitial A E/ S A E re p ort, t he i n vesti gat or is re q uire d t o pr oacti vel y f oll o w eac h partici pa nt at s u bse q ue nt visits/c o ntacts. All A Es/ S A E s a n d n o n -seri o us A Es of s pecial i nterest (as defi ne d i n Secti o n 9. 2. 8 ) will be f oll o we d u ntil res ol uti o n, sta biliz ati o n, u ntil t he e ve nt is ot her wise e x plai ne d, or t he partici pa nt is l ost t o f oll o w - u p (as defi ne d i n Secti o n 8. 3 ). T he i n vesti gat or is o bli gate d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal meas ure me nts a n d/ or e val uati o ns as me dical l y i n dicate d or as re q ueste d b y t he s p o ns or t o el uci date t he na t ure a n d/ or ca usality of t he A E or S A E as f ull y as p ossi ble. T his ma y i ncl u de a d diti o nal la b orat or y tests or i n vesti gati o ns, hist o pat h ol o gical e xa mi nati o ns, or c o ns ultati o n wit h ot her healt h care pr ofessi o nals. If a partici pa nt dies d uri n g partici pati o n i n t he st u d y or d uri n g a rec o g nize d f oll o w-u p peri o d, t he i n vesti gat or will pr o vi de t he s p o ns or wit h a c o p y of a n y p ost m orte m fi n d i n gs i ncl u di n g hist o pat h ol o g y . Ne w or u p date d i nf or mati o n will be rec or de d i n t he ori gi nall y c o m plete d C R F. T he i n vesti gat or will s u b mit a n y u p date d S A E data t o t he s p o ns or wit hi n 2 4 h o urs of recei pt of t he i nf or mati o n. 9. 2. 4. Re g ul at or y Re p orti n g Re q uire me nts f or S A E s  Pr o m pt n otificati o n b y t he i n vesti gat or t o t he sp o ns or of a n S A E is esse ntial s o t hat le gal o bli gati ons a n d et hical res p o nsi bilities t o war ds t he safet y of partici pa nt s a n d t he safety of a st u d y treat me nt u n der cli nical i n vesti gati o n are met.  T he sp o ns or has a le gal res p o nsi bilit y t o n otif y b ot h t he l ocal re g ulat or y a ut h orit y a n d ot her re g ulat or y a ge ncies a b o ut t he safet y of a st u d y treat me nt u n der cli nical i n vesti gati o n. T he sp o ns or will c o m pl y wit h c o u ntr y-s pecific re g ulat or y re q uire me nts relati n g t o safety re p orti n g t o t he re g ulat or y a ut h orit y, i nstit uti o nal re vie w b oar ds (IR B s)/i n de pe n de nt et hics c o m mittees (I E Cs), a n d i n vesti gat ors.  I n vesti gat or safet y re p orts m ust be pre pare d f or s us pecte d u ne x pecte d seri o us a d verse reacti o ns ( S U S A Rs) acc or di n g t o l ocal re g ulat or y re q uire me nts a n d sp o ns or p olic y a n d f or war de d t o i n vesti gat ors as necessar y.  A n i n vesti gat or w h o recei ves a n i n vesti gat or safet y re p ort descri bi n g a S A E or ot her s pecific safet y i nf or mati o n (e g, s u m mar y or listi n g of S A Es) fr o m t he sp o ns or will re vie w a n d t he n file it al o n g wit h t he I B a n d will n otif y t he I R B/I E C, if a p pr o priate acc ordi n g t o l ocal re q uire me nts . 9. 2. 5. C ar di o v asc ul ar a n d De at h E ve nts N ot a p plica ble"
47,page_47,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 79. 2. 6. Dise ase -Rel ate d E ve nts a n d/ or Dise ase -Rel ate d O utc o mes N ot Q u alif yi n g as A E s or S A Es N ot a p plica ble 9. 2. 7. Pre g n a nc y  Details of all pre g na ncies i n fe male partici pa nt s will be c ollecte d after t he start of st u d y treat me nt a n d u ntil 3 0 da y s after t he last d ose. 9. 2. 8. A d verse E ve nts of S peci al I nterest 9. 2. 8. 1. A d verse E ve nt s of S peci al I nterest A Es of s pecial i nterest are defi ne d as A Es of s p hi ncter of O d di s pas m, pa ncreatitis, a n d se vere c o nsti pati o n. T hese e ve nts m ust be re p orte d t o t he s p o ns or e x pe diti o usl y , as descri be d bel o w. Gi ve n t he μ -o pi oi d rece pt or a g o nis m of el u xa d oli ne, t here is a p ote ntial f or i ncrease d ris k of s p hi ncter of O d di s pas m, res ulti n g i n pa ncreatitis or he patic e nzy m e ele vati o n ass ociate d wit h ac ute a b d o mi nal pai n (e g, biliar y -t ype pai n), es peciall y d uri n g t he first fe w wee ks of treat me nt, i n partici pa nt s ta ki n g el u xa d oli ne, partic ularl y i n partici pa nt s wit h o ut a gall bla dder. Pa ncreatitis, wit h or wit h o ut s p hi ncter of O d di s pas m has bee n re p orte d i n patie nts ta ki n g el u xa d oli ne, i ncl u di n g seri o us cases res ulti n g i n h os pitalizati o n, pri maril y i n patie nts wit h o ut a gall bla d der. Fatal cases ha ve als o bee n re p orte d i n patie nts wit h o ut a gall bla d der. Partici pa nt s m ust be i nstr ucte d t o st o p t he st u d y treat me nt a n d see k me dical atte nti o n if t he y e x perie nce s y m pt o ms s u g gesti ve of s p hi ncter of O d di s pas m s uc h as ac ute w orse ni n g of a b d o mi nal pai n (e g, ac ute e pi gastric or biliar y [ie, ri g ht u p per q ua dra nt] pai n) t hat ma y ra diate t o t he bac k or s h o ul der, wit h or wit h o ut na usea a n d v o miti n g a n d/ or if t he y e x perie nce sy m pt o ms s u g gesti ve of pa ncreatitis s uc h as ac ute a b d o mi nal or e pi gastric pai n ra diati n g t o t he bac k. C o nsti pati o n was t he m ost fre q ue nt A E re p orte d i n st u dies of el u xa d oli ne f or I B S-D. Per t he U S Prescri bi n g I nf or mati o n, el u xa d oli ne is t o be disc o nti n ue d i n partici pa nt s w h o de vel o p se vere c o nsti pati o n. T o e ns ure t he i n vesti gat or is ma de a ware of se vere c o nsti pati o n (ie, t he partici pa nt is e x perie nci n g se vere disc o mf ort t hat se verely li mits or pre ve nts his/ her perf or ma nce of n or mal acti vities, or re prese nts a defi nite hazar d t o healt h t hat has or c o ul d res ul t i n h os pitalizati o n a n d prescri pti o n dr u g t hera p y) e pis o des , a n alert will be se nt t o t he in vesti gat or if a partici pa nt fails t o rec or d a b o wel m o ve me nt f or 3 c o nsec uti ve da ys i n his/her e Diar y . O nce n otifie d, t he in vesti gat or m ust c o ntact t he partici pa nt t o re vie w t he partici pa nt ’s stat us as s o o n as p ossi ble t o assess t he se verit y of his/ her c o nsti pati o n or t he prese nce of a ny se q uelae of c o nsti pati o n. E ver y atte m pt s h o ul d be ma de t o reac h t he st u d y partici pa nt wit hi n 2 4 h o urs. A n u nsc he d ule d visit t o"
48,page_48,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 8f urt her e val uate t he partici pa nt 's stat us s h o ul d be arra nge d if dee me d warra nte d b y t he in vesti gat or. T he st u d y treat ment m ust be disc o nti n ue d if t he i n vesti gat or deter mi nes t hat se vere c o nsti pati o n is prese nt. If a partici pa nt is s us pecte d of e x perie nci ng pa ncreatitis, s p hi ncter of O d di s pas m, or se vere c o nsti pati o n, t he A E m ust be re p orte d t o t he sp o ns or's S A E mail b o x: I R- Cli nical - S A E @aller ga n.c o m wit hi n 2 4 h o urs o n a n S A E F or m f or Cli nical Trials; i n t he a bse nce of sca n ni n g or e maili n g, t he S A E f or m ma y be fa xe d t o + 1 -7 1 4 -7 9 6 -9 5 0 4 ."
49,page_49,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 4 99. 2. 9. Me dic ati o n Err ors Me dicati o n err or refers t o a n y u ni nte n de d err or i n t he d osi n g a n d/ or a d mi nistrati o n of t he st u d y treat me nt as per i nstr ucti o ns i n t he pr ot oc ol. Me dicati o n err ors ge nerally fall i nt o 4 cate g ories as f oll o ws:  Wr o n g st u d y dr u g/ de vice  W r o n g d ose (i ncl u di n g d osi n g re gi me n, stre n gt h, f or m, c o nce ntrati o n, a m o u nt)  W r o n g r o ute of a d mi nistrati o n  W r o n g p artici pa n t (ie, n ot a d mi nistere d t o t he i nte n de d p artici pa nt) 9. 3. Tre at me nt of O ver d ose Please refer t o t he U S prescri bi n g i nf or mati o n ( VI B E R ZI PI 2 0 1 7 ) f or t he treat me nt t o be gi ve n i n case of o ver d ose. 9. 4. S afet y Assess me nts Pla n ne d ti mep oi nts f or all safet y assess me nts are pr o vi de d i n t he S o A . 9. 4. 1. P h ysic al E x a m i n ati o ns  A p h y sical e xa mi nati o n will c o nsist of a f ull re vie w of all b o d y s ys te ms (e xcl u di n g rectal a n d pel vic e xa mi nati o ns) s yste ms.  In vesti gat ors s h o ul d pa y s pecial atte nti o n t o cli nical si g ns relate d t o pre vi o us seri o us ill nesses. 9. 4. 2. Vit al Si g ns  P ulse, res pirat or y rate, a n d bl o o d press ure will be assesse d."
50,page_50,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 0 Bl o o d press ure a n d p ulse meas ure me nts will be assesse d i n a sitti n g p ositi o n wit h a c o m pletel y a ut o mate d de vice. Ma n ual tec h ni q ues will be use d o nl y if a n a ut o mate d de vice is n ot a vaila ble.  Vital si g ns will be meas ure d after at least 5 mi n utes rest f or t he partici pa nt i n a q uiet setti n g wit h o ut distracti o ns (e g, tele visi o n, cell p h o nes). O ne rea di n g eac h of p ulse, res pirat or y rate, a n d bl o o d press ure will be ta ke n.  Hei g ht a n d wei g ht will als o be meas ure d a n d rec or de d as s pecifie d i n t he S o A . 9. 4. 3. C li nic al S afet y L a b or at or y Assess me nts  See A p pe n di x 2 , Secti o n 1 2. 2 f or t he list of cli nical la b orat or y tests t o be perf or me d a n d t he S o A f or t he ti mi n g a n d fre q ue nc y.  T he i n vesti gat or m ust re vie w t he la b orat or y re p ort, d oc u me nt t his re vie w, a n d rec or d a n y cli nicall y rele va nt c ha n ges occ urri n g d uri n g t he st u d y i n t he A E secti o n of t he C R F. T he la b orat or y re p orts m ust be file d wit h t he s o urce d oc u me nts. Cli nicall y si g nifica nt a b n or mal la b orat or y fi n di n gs are t h ose w hic h are n ot ass ociate d wit h t he u n derl yi n g d isease, u nless j u d ge d by t he i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt’ s c o n diti o n.  All la b orat or y tests wit h val ues c o nsi dere d cli nicall y si g nifica ntly a b n or mal d uri n g partici pati o n i n t he st u d y or wit hi n 2 wee ks after t he last d ose of st u d y treat me nt s h o ul d be re peate d u ntil t he val ues ret ur n t o n or mal or baseli ne or are n o l o n ger c o nsi dere d cli nicall y si g nifica nt by t he i n vesti gat or or me dical m o nit or .  If s uc h val ues d o n ot ret ur n t o n or mal/ baseli ne wit hi n a peri o d of ti me j u d ge d reas o na ble by t he i n vesti gat or, t he eti ol o g y s h o ul d be i de ntifie d a n d t he sp o ns or n otifie d.  All pr ot oc ol -re q uire d la b orat or y assess me nts, as defi ne d i n A p pe n di x 2 , Secti o n 1 2. 2 , m ust be c o n d ucte d i n acc or da nce wit h t he S o A .  If la b orat or y val ues fr o m n o n -pr ot oc ol s pecifie d la b orat or y assess me nts perf or me d at t he i nstit uti o n’s l ocal la b orat or y re q uire a c ha n ge i n partici pa nt ma na ge me nt or are c o nsi dere d cli nica ll y si g nifica nt b y t he i n vesti gat or (e g, S A E or A E or d ose m o dificati o n) , t he n t he res ults m ust be rec or de d i n t he e CR F. 9. 4. 4. S uici d al Ris k M o nit ori n g S uici dal Ris k M o nit ori n g is n ot a p plica ble t o t his st u d y . 9. 5. P h ar m ac o k i netics"
51,page_51,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 19. 6. P h ar m ac o d y n a mics T he p har mac o d y na mic effects of el u xa d oli ne o n t he altere d b o wel ha bits of I B S -D will be assesse d via efficac y assess me nts pre vi o usl y descri be d. 9. 7. Ge netics Ge netics are n ot e val uate d i n t his st u d y . 9. 8. Bi o m ar k ers Bi o mar kers are n ot e val uate d i n t his st u d y . 9. 9. He alt h Ec o n o mic s or Me dic al Res o urce Utiliz ati o n a n d He alt h Ec o n o mic s Healt h ec o n o mics/ Me dical res o urce utilizati o n a n d healt h ec o n o mics para meters a re n ot e val uate d i n t his st u d y.
52,page_52,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 21 0. St atistic al C o nsi der ati o ns 1 0. 1. S a m ple Size Deter mi n ati o n T he t otal sa m ple size f or t his st u d y is 2 4 partici pa nt s ( 1 2 partici pa nt s wit h B A M a n d 1 2 partici pa nts wit h o ut B A M). N o f or mal sa m ple size esti mati o n will be calc ulate d beca use t he sa m ple size f or t his st u d y is n ot base d o n statistical c o nsi derati o n. 1 0. 2. P o p ul at i o ns f or A n al yses T he a nal ys is p o p ulati o ns will c o nsist of partici pa nt s as defi ne d i n Ta ble 1 0 – 1 . T a ble 1 0 – 1 A n al ysis P o p ul ati o ns P o p ul ati o n Defi niti o n St u d y Tre at me nt Scree ne d All scree ne d partici pa nt s w h o si g n i nf or me d c o nse nt — E nr olle d All partici pa nts i n Scree ne d P o p ulati o n w h o meet t he eli gi bilit y criteria a n d e nter t he o pe n-la bel treat me nt peri o dA ssi g n me nt M o difie d i nte nt -t o- treat ( mI T T)All partici pa nt s i n E nr olle d P o p ulati o n wit h ≥ 1 p ost baseli ne assess me nt f or B S F S A ssi g n me nt Safet y All partici pa nt s w h o recei ve d ≥ 1 a d mi nistrati o n of st u d y treat me ntAct ual recei ve d B S F S = Brist ol St o ol F or m Scale 1 0. 3. St atistic al A n al yses T he statistical a nal ys is pla n ( S A P) will be de vel o pe d a n d fi nalize d bef ore data base l oc k a n d will descri be t he partici pa nt p o p ulati o ns t o be i ncl u de d i n t he a nalys es, a n d pr oce d ures f or acc o u nti n g f or missi n g, u n use d, a n d s p uri o us data. T his secti o n is a s u m mar y of t he pla n ne d statistical a nal ys es of t he pri mar y a n d sec o n dar y e n d p oi nts. 1 0. 3. 1. Ke y St atistic al Met h o d ol o g y T he met h o d ol o gies defi ne d i n Ta ble 1 0 – 2 a p pl y as s pecifie d t o i n di vi d ual e n d p oi nts. All efficac y e n d p oi nts will be s u m marize d b y partici pa nt c o h ort ( B A M or N o n -B A M) descri pti vel y."
53,page_53,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 3T a ble 1 0 – 2 St atistic al Met h o d ol o g y M e t h o d ol o g y Descri pti o n Cate g orical c o u nts  N u m ber of partici pa nts i n i n di vi d ual cate g ories o Partici pa nts wit h ≥ 1 q ualif yi n g e ve nt c o u nte d o nce per i n di vi d ual cate g or y Cate g orical descri pti ves N u m ber a n d perce nta ge of partici pa nts i n i n di vi d ual cate g ories o Partici pa nts wit h ≥ 1 q ualif yi n g e ve nt c o u nte d o nce per i n di vi d ual cate g or y  [ O pti o nal] N 1 if perce nta ge de n o mi nat or ≠ n u m ber of partici pa nts i n t he p o p ulati o n (sta n dar d perce nta ge de n o mi nat or) o N 1 = partici pa nts w it h n o n missi n g baseli ne val ue P C S descri pti ves  N u m ber a n d perce nta ge of partici pa nts meeti n g P C S criteria o Partici pa nts wit h ≥ 1 q ualif yi n g e ve nt c o u nte d o nce per P C S cate g or y  Perce nta ge de n o mi nat or = n u m ber of partici pa nts wit h n o n missi n g baseli ne a n d ≥ 1 n o n missi n g p ost baseli ne assess me nt o U ne val ua ble assess me nts c o nsi dere d missi n g E ve nt descri pti ves  N u m ber a n d perce nta ge of e ve nts i n i n di vi d ual cate g ories o E ve nts c o u nte d i n di vi d uall y f or eac h i nsta nce  Perce nta ge de n o mi nat or = t otal n u m ber of e ve nts S hift a nal ysis  N u m ber a n d perce nta ge of partici pa nts i n i n di vi d ual baseli ne a n d p ost baseli ne cate g ories  Perce nta ge de n o mi nat or = n u m ber of partici pa nts i n i n di vi d ual baseli ne cate g ories  N 1 = partici pa nts w it h n o n missi n g val ues at b ot h baseli ne a n d t he s pecifie d p ost baseli ne a nal ysis visit C o nti n u o us descri pti ves N 1, mea n, S D, me dia n, mi ni m u m, ma xi m u m  N 1 = partici pa nts w it h n o n missi n g val ue C F B descri pti ves  C o nti n u o us descri pti ves f or baseli ne, p ost baseli ne, a n d C F B val ues  N 1 = partici pa nts w it h n o n missi n g val ues at b ot h baseli ne a n d t he s pecifie d p ost baseli ne a nal ysis visit C F B = c ha n ge fr o m baseli ne; P C S = p ote ntiall y cli nicall y si g nifica nt 1 0. 3. 2. Effic ac y A n al yses T he f oll o wi n g pri mar y a n d sec o n dar y efficac y e n d p oi nts will be s u m marize d b y c o h ort ( B A M or N o n- B A M) f or t he m I T T p o p ulati o n. All ot her efficac y e n d p oi nts a n d a nal yses will be defi ne d i n t he S A P. Descri pti o ns i n Ta ble 1 0 – 3a n d Ta ble 1 0 – 4 m a y be li n ke d t o t he assess me nt(s) a n d/ or o bjecti ve(s). T a ble 1 0 – 3 Pri m ar y Effic ac y E n d p oi nt E n d p oi nt Descri pti o n Ti mi n g M e t h o d ol o g y C ha n ge fr o m baseli ne i n a vera ge B S F S Treat me nt Peri o d Descri pti ve"
54,page_54,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 4E n d p oi nt Descri pti o n Ti mi n g M e t h o d ol o g y sc ore o ver 4 wee ks of treat me nt peri o d s u m mar y N ote: A nal ysis visits will be i n t he S A P. B S F S = Brist ol St o ol F or m Scale T a ble 1 0 – 4 Sec o n d ar y Effic ac y E n d p oi nts E n d p oi nt Descri pti o n Ti mi n g M e t h o d ol o g y C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y b o wel m o ve me nt fre q ue nc y d uri n g t he treat me nt peri o dTreat me nt Peri o d Descri pti ve s u m mar y C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y w orst a b d o mi nal pai n sc ores d uri n g t he treat me nt peri o dTreat me nt Peri o d Descri pti ve s u m mar y C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y worst a b d o mi nal pai n sc ores d uri n g t he treat me nt peri o dTreat me nt Peri o d Descri pti ve s u m mar y C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of ur ge nc y -free da ys i n a wee k d uri n g t he treat me nt peri o dTreat me nt Peri o d Descri pti ve s u m mar y C ha n ge fr o m baseli ne i n t he 4 -wee k a vera ge of dail y bl oati n g sc ores d uri n g t he treat me nt peri o dTreat me nt Peri o d Descri pti ve s u m mar y C ha n ge fr o m baseli ne i n I B S -Q O L sc ore at t he e n d of t he treat me nt peri o dTreat me nt Peri o d Descri pti ve s u m mar y C ha n ge fr o m baseli ne i n ser u m 7 α C 4 le vels at t he e n d of t he treat me nt peri o dTreat me nt Peri o d Descri pti ve s u m mar y Pr o p orti o n of partici pa nts wit h a n y fecal i nco nti ne nce d uri n g t he treat me nt p eri o dTreat me nt Peri o d Descri pti ve s u m mar y N ote: A nal ysis visits will be i n t he S A P. 7 α C 4 = 7a -h y dr o x y - 4-c h oleste n- 3-o ne; I B S-Q O L = i rrita ble b o wel s y n dr o me -q ualit y of life 1 0. 3. 3. S afet y A n al yses T he f oll o wi n g safet y cate g ories will be s u m marize d as a p pr o priate (e g, cate g orical or c o nti n u o us descri pti ves, s hift ta bles) f or t he safet y p o p ulati o n a n d will be f ull y defi ne d i n t he S A P.  Seri o us A d verse E ve nts  A d verse e ve nts  Cli nical la b o rat or y assess me nts  P ote ntial H y ’s la w cases  P ote ntial Dr u g I n d uce d Li ver I nj ur y Cases"
55,page_55,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 5 Vital si g ns i ncl u di n g wei g ht  P h y sical e xa mi nati o ns 1 0. 3. 4. P h ar m ac o ki netic A n al yses 1 0. 3. 5. Ot her A n al yses N o ne 1 0. 3. 6. I nteri m A n al yses N o i nteri m a nal ys is will be c o n d ucte d.
56,page_56,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 61 1. Refere nces Aziz I, M u mtaz S, B h ola h H, C h o w d h ur y F U, Sa n ders D S, F or d A C. Hi g h pre vale nce of i di o pat hic bile aci d diarr hea a m o n g patie nts wit h diarr hea-pre d o mi na nt irrita ble b o wel s y n dr o me base d o n R o me III criteria. Cli n Gastr oe nter ol He pat ol. 2 0 1 5; 1 3: 1 6 5 0 -1 6 5 5. Baj or A, T ör n bl o m H, R u dli n g M, U n g K A, Si mré n M. I ncrease d c ol o nic bile aci d e x p os ure: a rele va nt fact or f or sy m pt o ms a n d treat me nt i n I B S. G ut. 2 0 1 5; 6 4: 8 4 -9 2. Ca milleri M, Na dea u A, Tre mai ne WJ, L a msa m J, B urt o n D, O d u nsi S, et al. Meas ure me nt of ser u m 7al p ha-h y dr o x y - 4- c h oleste n- 3-o ne ( or 7al p ha C 4), a s urr o gate test f or bile aci d mala bs or pti o n i n healt h, ileal disease a n d irrita ble b o wel s y n dr o me usi n g li q ui d c hr o mat o gra p h y - ta n de m mass s pectr o metr y. Ne ur o gastr oe nter ol M otil. 2 0 0 9; 2 1: 7 3 4-e 4 3. Ca milleri M. Peri p h eral mec ha nis ms i n irrita ble b o wel s yn dr o me. N E n gl J Me d. 2 0 1 2; 3 6 7: 1 6 2 6 -1 6 3 5. Ca milleri M. A d va nces i n u n dersta n di n g of bile aci d diarr hea. E x pert Re v Gastr oe nter ol He pat ol. 2 0 1 4; 8( 1): 4 9 – 6 1. Ca milleri M, B usci gli o I, Ac osta A, S hi n A, Carls o n P, B urt o n D, et al. Effect of i ncrease d bile aci d s ynt hesis or fecal e xcreti o n i n irrita ble b o wel s y n dr o me -diarr hea. A m J Gastr oe nter ol. 2 0 1 4 ; 1 0 9: 1 6 2 1-1 6 3 0. Ca milleri M. Bile Aci d Diarr hea: Pre vale nce, Pat h o ge ne sis, a n d T hera p y. G ut a n d Li ver. 2 0 1 5; 9( 3): 3 3 2 -3 3 9. C he y W D, K urla n der J, Es wara n S. Irrita ble b o wel s yn dr o me: a cli nical re vie w. J A M A 2 0 1 5; 3 1 3: 9 4 9 - 95 8. Dr oss ma n D A, Patric k D L, W hite hea d W E, T o ner B B, Dia ma nt N E, H u Y, et al . F urt her vali dati o n of t he I B S- Q O L: a disease -s pecific q ualit y-of -life q uesti o nnaire. A m J Gastr oe nter ol 2 0 0 0; 9 5: 9 9 9 -1 0 0 7 . Dr oss ma n D A. T he f u ncti o nal gastr oi ntesti nal dis or ders a n d t he R o me III pr ocess. Gastr oe nter ol o g y . 2 0 0 6;1 3 0( 5): 1 3 7 7 -1 3 9 0. E us ufzai S, A xels o n M, A n geli n B, Ei narss o n K. Ser u m 7 al p ha -h y dr o x y- 4-c h oleste n- 3- o ne c o nce ntrati o ns i n t he e val uati o n of bile aci d mala bs or pti o n i n patie nts wit h diarr h oea: c orrel ati o n t o Se H C A T test. G ut. 1 9 9 3;3 4: 6 9 8 – 7 0 1. F D A G ui da nce f or I n d ustr y , Dr u g-I n d uce d Li ver I nj ur y: Pre mar keti n g Cli nical E val uati o n, J ul y 2 0 0 9 htt ps:// w w w.f da. g o v/ d o w nl oa ds/ dr u gs/ g ui da ncec o m plia ncere g ulat or yi nf or mati o n/ g ui da nces/ uc m 1 7 4 0 9 0. p df Gral ne k I M, Ha y s R D, Kil b o ur ne A, Nali b off B, Ma yer E A. T he i m pact of irrita ble b o wel s yn dr o me o n healt h -relate d q ualit y of life. Gastr oe nter ol o g y . 2 0 0 0; 1 1 9:6 5 4 -6 6 0."
57,page_57,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 7H ulisz D. T he b ur de n of ill ness of irrita ble b o wel s y n dr o me: c urre nt c halle n ges a n d h o pe f or t he fut ure. J Ma na g Care P har m 2 0 0 4; 1 0: 2 9 9 -3 0 9. Isla m R S, Di Baise J K. Bile aci ds: a n u n derrec o g nize d a n d u n dera p preciate d ca use of c hr o nic diarr hea. Practical Gastr oe nter ol 2 0 1 2; 3 6( 1 0): 3 2 -4 4. Lac y B E, Meari n F, C ha n g L, C he y W D, Le m b o AJ, Si mre n M, S piller R. B o wel Dis or ders. Gastr oe nter ol. 2 0 1 6; 1 5 0: 1 3 9 3 – 1 4 0 7. Le m b o AJ, Lac y B E, Z uc ker ma n MJ, Sc he y R, D o ve LS, A n drae D A et al . El u xa d oli ne f or Irrita ble B o wel Sy n dr o me wit h Diarr hea. N E n gl J Me d. 2 0 1 6; 3 7 4( 3): 2 4 2 - 25 3. L o n gstret h G F, T h o m ps o n W G, C he y W D, H o u g ht o n L A, Meari n F, S piller R C . F u ncti o nal b o wel dis or ders. Gastr oe nter ol o g y . 2 0 0 6;1 3 0( 5): 1 4 8 0 -1 4 9 1. L o vell R M, F or d A C. Gl o bal Pre vale nce of a n d Ris k Fact ors f or Irrita ble B o wel S y n dr o me: A Meta -a nal ysis. Cli n Gastr oe nter ol He pat ol. 2 0 1 2; 1 0( 7): 7 1 2 -7 2 1. O d u nsi -S hi y a n ba de S T, Ca milleri M, Mc Ki nzie S, B u rt o n D, Carls o n P, B usci gli o I A et al . Effects of c he n o de o x yc h olate a n d a bile ac i d se q uestra nt, c olese vela m, o n i ntesti nal tra nsit a n d b o wel f u ncti o n. Cli n Gastr oe nter ol He pat ol . 2 0 1 0; 8: 1 5 9 -1 6 5. O' D o n nell L J D, Heat o n K W. Pse u d o-diarr hea i n t he irr ita ble b o wel s y n dr o me: patie nts’ rec or ds of st o ol f or m reflect tra nsit ti me w hile st o o l fre q ue nc y d oes n ot. G ut 1 9 8 8; 2 9:A 1 4 5 5 . Paré P, Gra y J, La m S, Bals ha w R, K h oras he h S, Bar bea u M et al. Healt h -relate d q uality of life, w or k pr o d ucti vit y , a n d healt h care res o urce utilizati o n of s u bjects wit h irrita ble b o wel sy n dr o me: baseli ne res ults fr o m L O GI C ( L o n git u di nal O utc o mes St u d y of Gastr oi ntesti nal S ym pt o ms i n Ca na da), a nat uralistic st u d y . Cli n T her. 2 0 0 6; 2 8:1 7 2 6 -1 7 3 5. Patric k D L, Dr oss ma n D A, Fre deric k I O, Di Cesare J, P u der K L. Q ualit y of life i n pers o ns wit h irrita ble b o wel sy n dr o me: de vel o p me nt a n d vali dati o n of a ne w meas ure. Di g Dis Sci 1 9 9 8; 4 3: 4 0 0 - 41 1 . Sa uter G H, M ü nzi n g W, v o n Ritter C, Pa u m gart ner G. Bile aci d mala bs or pti o n as a ca use of c hr o nic diarr hea: dia g n ostic val ue of 7al p ha -h y dr o x y - 4-c h oleste n- 3-o ne i n ser u m. Di g Dis Sci. 1 9 9 9; 4 4 :1 4 -1 9. S hi n A, Ca milleri M, Vija y var gi ya P, et al. B o wel f u ncti o ns, fecal u nc o nj u gate d pri mar y a n d sec o n dar y bile aci ds, a n d c ol o nic tra nsit i n patie nts wit h irrita ble b o wel sy n dr o me. Cli n Gastr oe nter ol He pat ol. 2 0 1 3; 1 1( 1 0): 1 2 7 0 -1 2 7 5.e 1. Vale nti n N, Ca mil leri M, Alta yar O, Vija yvar gi ya P, Ac osta A, Nels o n A D, M ura d M H. Bi o mar kers f or bile aci d diarr h oea i n f u ncti o nal b o wel dis or der wit h diarr h oea: a s ys te matic re vie w a n d meta-a nal ys is. G ut. 2 0 1 6 Dec; 6 5( 1 2): 1 9 5 1 -1 9 5 9 . VI B E R ZI ™ Prescri bi n g i nf or mati o n Aller g a n U S A, I nc. Ir vi ne, C A 9 2 6 1 2 2 0 1 5 ; htt ps:// dail y me d. nl m. ni h. g o v/ dail y m e d/ dr u gI nf o.cf m?seti d = 7 8 2 1 b d 4 0 -4c 8 4 -4 9 8 4 -9 5 1 b - 6 4 3 6ae 2 0 4 2 1a"
58,page_58,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 8Vija y var gi ya P, Ca milleri M, Carls o n P, L ue ke A, O' Neill J, B urt o n D et al. Perf or ma nce c haracteristics of ser u m C 4 a n d F G F 1 9 meas ure me nts t o e xcl u de t he dia g n osis of bile aci d diarr h oea i n I B S -diarr h oea a n d f u ncti o nal diarr h oea. Ali me nt P har mac ol T her. 2 0 1 7 ; 4 6( 6): 5 8 1-5 8 8. Vija y var gi ya P, Ca milleri M, C he di d V, et al. A nal ysis of Fecal Pri mar y Bile Aci ds Detects I ncrease d St o ol Wei g ht a n d C ol o nic Tra nsit i n Patie nts Wit h C hr o nic F u ncti o nal Diarr hea. Cli n Gastr oe nter ol He pat ol. 2 0 1 8. Wa de P R, Pal mer J M, Mc Ke n ne y S, Ke ni gs V, C he valier K, M o ore B A, et al. M o d ulati o n of gastr oi ntesti nal f u ncti o n b y M u Delta, a mi xe d µ o pi oi d rece pt or a g o nist/ µ o pi oi d rece pt or a nta g o nist. Br J P har mac ol. 2 0 1 2 N o v ; 1 6 7( 5): 1 1 1 1-1 1 2 5. C orrecti o n t o title i n Br J P har mac ol. 2 0 1 3 ; 1 6 8: 5 1 8. Walters J R. Defi ni n g pri mar y bile aci d diarr hea: ma ki n g t he dia g n osis a n d rec o g nizi n g t he dis or der. E x p Re v Gastr oe nter o l He pat ol. 2 0 1 0; 4( 5): 5 6 1-5 6 7. We dla ke L, A’ Her n R, R ussell D, T h o mas K, Walters J R, A n dre ye v HJ. S yste matic re vie w: t he pre vale nce of i di o pat hic bile aci d mala bs or pti o n as dia g n ose d b y Se H C A T sca n ni n g i n patie nts wit h diarr h oea- pre d o mi na nt irrita ble b o wel s y n dr o me. Ali me nt P har mac ol . 2 0 0 9;3 0: 7 0 7 -7 1 7. W o n g B S, Ca milleri M, Carls o n P, Mc Ki nzie S, B usci gli o I, B o n dar O et al. I ncrease d bile aci d bi os y nt hesis is ass ociate d wit h irrita ble b o wel s y n dr o me wit h diarr hea. Cli n Gastr oe nter ol He pat ol. 2 0 1 2; 1 0: 1 0 0 9 -1 0 1 5."
59,page_59,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 5 91 2. A p pe n dices 1 2. 1. A p pe n di x 1: A b bre vi ati o ns a n d Tr a de m ar ks 7 α C 4 7a -h y dr o x y- 4-c h oleste n- 3- o ne A E a d verse e ve nt A E SI a d verse e ve nt of s pecial i nterest A L T ala ni ne a mi n otra nsferase A S T as partate a mi n otra nsferase A U C ta u area u n der t he plas ma c o nce ntrati o n -ti me c ur ve d uri n g t he d osi n g i nter val B A bile aci d B A M bile aci d mala bs or pti o n BI D t wice dail y B MI b o d y mass i n de x B S F S Brist ol St o ol F or m Scale C DI S C Cli nical Data I nterc ha n ge Sta n dar ds C o ns orti u m C F B c ha n ge fr o m baseli ne C F R C o de of Fe deral Re g ulati o ns C L a p pare nt cleara nce Cma x ma xi m u m plas ma c o nce ntrati o n Cmi n mi ni m u m plas ma c o nce ntrati o n C N S ce ntral ner v o us s ys te m C O N S O R T C o ns oli date d Sta n dar ds of Re p orti n g T rials D B S drie d bl o o d sa m ple DI LI dr u g i n d uce d li ver i nj ur y e C R F electr o nic case re p ort f or m e Diar y electr o nic diar y E M A E ur o pea n Me dici nes A ge nc y E O T e n d of treat me nt E T earl y ter mi nati o n F D A U S F o o d a n d Dr u g A d mi nistrati o n F GI D f u ncti o nal gastr oi ntesti nal dis or ders
60,page_60,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 0F S H f ollicle sti m ulati n g h or m o ne G C P G o o d Cli nical Practice GI gastr oi ntesti nal H R T h or m o nal re place me nt t hera p y I B In vesti gat or ’s Br oc h ure I B S irrita ble b o wel sy n dr o me I B S- C irrita ble b o wel sy n dr o me wit h c o nsti pati o n I B S- D irrita ble b o wel sy n dr o me wit h diarr hea I B S- M irrita ble b o wel sy n dr o me wit h c o nsti pati o n a n d diarr hea I B S-Q O L irrita ble b o wel sy n dr o me -q ualit y of life I B S- U irrita ble b o wel sy n dr o me ( u ns pecifie d) I CF i nf or me d c o nse nt f or m I C H I nter nati o nal C o nfere nce o n Har m o nisati o n I E C I n de pe n de nt Et hics C o m mittee I N R i nter nati o nal n or malize d rati o I RB I nstit uti o nal Re vie w B oar d L C -M S/ M S li q ui d c hr o mat o gra p hy ta n de m -mass s pectr o metr y mI T T m o difie d i nte nt -t o-treat N CI Nati o nal Ca ncer I nstit ute N O N M E M n o nli near mi xe d effects m o deli n g P K p har mac o ki netic P T pr ot hr o m bi n ti me R o me R o me Dia g n ostic Criteria f or F u ncti o nal Gastr oi ntesti nal Dis or ders S A E seri o us a d verse e ve nt S A P statistical a nal ysis pla n Se H C AT7 5Sele ni u m -h o m oc h olic aci d ta uri ne S O s p hi ncter of O d di S o A sc he d ule of acti vities S U S A R s us pecte d u ne x pecte d seri o us a d verse reacti o n t1/ 2 half -life tma x ti me t o C ma x U L N u p per li mit of n or mal V a p pare nt v ol u me of distri b uti o n W O C B P w o ma n of c hil d beari n g p ote ntial
61,page_61,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 1δ O R delta -o pi oi d rece pt or κ O R ka p pa- o pi oi d rece pt or µ O R m u -o pi oi d rece pt or
62,page_62,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 21 2. 2. A p pe n di x 2: Cli nic al L a b or at or y Tests
63,page_63,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 31 2. 3. A p pe n di x 3: St u d y G o ver n a nce C o nsi der ati o ns Re g ul at or y a n d Et hic al C o nsi der ati o ns T his st u d y will be c o n d ucte d i n acc or da nce wit h t he pr ot oc ol a n d wit h t he f oll o wi n g:  C o nse ns us et hic al pri nci ples deri ve d fr o m i nter nati o nal g ui deli nes i ncl u di n g t he Declarati o n of Helsi n ki a n d C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical Scie nces ( CI O M S) i nter nati o nal et hical g ui deli nes  A p plica ble I CH G C P g ui deli nes  A p plica ble la ws a n d re g ulati o ns  T he pr ot oc ol, pr ot oc ol a me n d me nts, I CF , I B, a n d ot her rele va nt d oc u me nts ( e g, a d vertise me nts) m ust be s u b mitte d t o a n IR B/I E C b y t he i n vesti gat or a n d re vie we d a n d a p pr o ve d b y t he I RB/I E C bef ore t he st u d y is i nitiate d.  A n y a me n d me nts t o t he pr ot oc ol will re q uire I R B/IE C a p pr o val bef ore i m ple me ntati o n of c ha n ges ma de t o t he st u d y desi g n, e xce pt f or c ha n ges necessar y t o eli mi nate a n i m me diate hazar d t o st u d y partici pa nt s.  T he i n vesti gat or will be res p o nsi ble for t he f oll o wi n g: o Pr o vi di n g writte n s u m maries of t he stat us of t he st u d y t o t he I R B/ IE C a n n uall y or m ore fre q ue ntl y i n acc or da nce wit h t he re q uire me nts, p olicies, a n d pr oce d ures esta blis he d b y t he I R B/ IE C o N otif y i n g t he I R B/I E C of S A Es or ot her si g nifica nt safety fi n di n gs as re q uire d by I RB/I E C pr oce d ures o Pr o vi di n g o versi g ht of t he o verall c o n d uct of t he st u d y at t he site a n d a d here nce t o re q uire me nts of a p plica ble l ocal re g ulati o ns , f or e xa m ple 2 1 C F R, I C H g ui deli nes, t he I R B/I E C, a n d E ur o pea n re g ulati o n 5 3 6/ 2 0 1 4 f or cli nical st u dies (if a p plica ble) Fi n a nci al Discl os ure I n vesti gat ors a n d s u bin vesti gat ors will pr o vi de t he sp o ns or wit h s ufficie nt, acc urate fi na ncial i nf or mati o n as re q ueste d t o all o w t he sp o ns or t o s u b mit c o m plete a n d acc urate fi na ncial certificati o n or discl os ure state me nts t o t he a p pr o priate re g ulat or y a ut h orities. I nvesti gat ors are res p o nsi ble f or pr o vi di n g i nf or mati o n o n fi na ncial i nterests d uri n g t he c o urse of t he st u dy a n d f or 1 y ear after c o m pleti o n of t he st u d y. I nf or me d C o nse nt Pr ocess  T he i n vesti gat or or his/ her re prese ntati ve will e x plai n t he nat ure of t he st u d y t o t he partici pa nt or his/ her le gall y a ut h orize d re prese ntati ve a n d a ns wer all q uesti o ns re gar di n g t he st u dy.  Partici pa nt s m ust be i nf or me d t hat t heir partici pati o n is v ol u n tar y. Partici pa nt s will be re q uire d t o si g n a state me nt of i nf or me d c o nse nt t hat meets t he re q uire me nts of"
64,page_64,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 42 1 C F R Part 5 0, l ocal re g ulati o ns, I C H g ui deli nes, Healt h I ns ura nce P orta bilit y a n d Acc o u nta bilit y Act (HI P A A ) re q uire me nts, w here a p plica ble, a n d t he I R B/I E C or st u dy site.  T he me dical rec or d m ust i ncl u de a state me nt t hat writte n i nf or me d c o nse nt was o btai ne d bef ore t he partici pa nt was e nr olle d i n t he st u d y a n d t he date t he writte n c o nse nt was o btai ne d. T he a ut h orize d pers o n o btai ni n g t he i nf or me d c o nse nt m ust als o si g n t he I CF.  Partici pa nt s m ust be re-c o nse nte d t o t he m ost c urre nt versi o n of t he I CF(s) d uri n g t heir partici pati o n i n t he st u d y .  A c o p y of t he I CF(s) m ust be pr o vi de d t o t he partici pa nt or t he partici pa nt’s le gall y a ut h orize d re p rese ntati ve. Partici pa nt s w h o are rescree ne d are re q uire d t o si g n a ne w I C F. D at a Pr otecti o n  Partici pa nts will be assi g ne d a u ni q ue i de ntifier b y t he sp o ns or . A n y partici pa nt rec or ds or datasets t hat are tra nsferre d t o t he sp o ns or will c o ntai n t he i de ntif ier o nl y; partici pa nt na mes or a n y i nf or mati o n w hic h w o ul d ma ke t he partici pa nt i de ntifia ble will n ot be tra nsferre d.  T he partici pa nt m ust be i nf or me d t hat his/ her pers o nal st u d y-relate d data will be use d b y the sp o ns or i n acc or da nce wit h l ocal data pr otecti o n la w. T he le vel of discl os ure m ust als o be e x plai ne d t o t he partici pa nt.  T he partici pa nt m ust be i nf or me d t hat his/ her me dical rec or ds ma y be e xa mi ne d b y Cli nical Q ualit y Ass ura nce a u dit ors or ot her a ut h orize d pers o n nel a p p oi nte d b y t he sp o ns or , b y a p pr o priate I R B/I E C me m bers, a n d b y i ns pect ors fr o m re g ulat or y a ut h orities. C o m mittees Str uct ure P u blic ati o n P olic y  Aller ga n as t he s p o ns or has pr o prietar y i nterest i n t his st u d y. A ut h ors hi p a n d ma n uscri pt c o m p ositi o n will reflect j oi nt c o o perati o n bet wee n t he i n vesti gat or a n d Aller ga n pers o n nel. A ut h ors hi p will be esta blis he d pri or t o t he writi n g of t he ma n uscri pt.  T h e sp o ns or will c o m pl y wit h t he re q uire me nts f or p u blicati o n of st u d y res ults. I n acc or da nce wit h sta n dar d e dit orial a n d et hical practice, t he sp o ns or will ge nerall y s u p p ort p u blicati o n of m ultice nter st u dies o nl y i n t heir e ntirety a n d n ot as i n di vi d ual site data.  A ut h ors hi p will be deter mi ne d b y m ut ual a gree me nt a n d i n li ne wit h Inter nati o nal C o m mittee of Me dical J o ur nal E dit ors a ut h ors hi p re q uire me nts ."
65,page_65,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 5Disse mi n ati o n of Cli nic al St u d y D at a D at a Q u alit y Ass ur a nce  All partici pa nt data relati n g t o t he st u d y will be rec o rde d o n pri nte d or electr o nic C R F s u nless tra ns mitte d t o t he sp o ns or or desi g nee electr o nicall y (e g, la b orat or y data). T he i n vesti gat or is res p o nsi ble f or verif yi n g t hat data e ntries are acc urate a n d c orrect by p h y sically or electr o nicall y si g ni n g t he C R F.  T he i n vesti gat or m ust mai ntai n acc urate d oc u me ntati o n (s o urce data) t hat s u p p orts t he i nf or mati o n e ntere d i n t he C R F.  T he i n vesti gat or m ust per mit st u d y -relate d m o nit ori n g, a u dits, I R B/I E C re vie w, a n d re g ulat or y a ge nc y i ns pecti o ns a n d pr o vi d e direct access t o s o urce data d oc u me nts.  T he sp o ns or or desi g nee is res p o nsi ble f or t he data ma na ge me nt of t hi s st u d y i ncl u di n g q ualit y c hec ki n g of t he data.  St u d y m o nit ors will perf or m o n g oi n g s o urce data verificati o n t o c o nfir m t hat data e ntere d i nt o t he C R F b y a ut h orize d site pers o n nel are acc urate, c o m plete, a n d verifia ble fr o m s o urce d oc u me nts; t hat t he safet y a n d ri g hts of partici pa nt s are bei n g pr otecte d; a n d t hat t he st u d y is bei n g c o n d ucte d i n acc or da nce wit h t he c urre ntl y a p pr o ve d pr ot oc ol a n d a n y ot her st u d y a gree me nts, I CH G C P, a n d all a p plica ble re g ulat or y re q uire me nts.  Rec or ds a n d d oc u me nts, i ncl u di n g si g ne d I C F s, pertai ni n g t o t he c o n d uct of t his st u d y m ust be retai ne d b y t he i n vesti gat or f or 1 5 ye ars after st u d y c o m pleti o n u nless l ocal re g ulati o ns or i nstit uti o nal p olicies re q uire a l o n ger rete nti o n peri o d. N o rec or ds ma y be destr o y e d d uri n g t he re te nti o n peri o d wit h o ut t he writte n a p pr o val of t he sp o ns or . N o rec or ds ma y be tra nsferre d t o a n ot her l ocati o n or part y wit h o ut writte n n otificati o n t o t he sp o ns or . S o urce D oc u me nts  S o urce d oc u me nts pr o vi de e vi de nce f or t he e xiste nce of t he partici pa nt a n d s u bsta ntiate t he i nte grity of t he data c ollecte d. S o urce d oc u me nts are file d at t he i n vesti gat or’s site.  Data re p orte d o n t he C R F or e ntere d i n t he e C R F t hat are tra nscri be d fr o m s o urce d oc u me nts m ust be c o nsiste nt wit h t he s o urce d oc u me nts or t he discre pa ncies m ust be e x plai ne d. T he i n vesti gat or ma y nee d t o re q uest pre vi o us me dical rec or ds or tra nsfer rec or ds, de pe n di n g o n t he st u d y. Als o, c urre nt me dica l rec or ds m ust be a vaila ble.  S o urce d oc u me nts i ncl u de a partici pa nt’s me dical rec or ds, h os pital c harts, cli nic c harts, t he i n vesti gat or’s partici pa nt st u d y files, as well as t he res ults of dia g n ostic tests s uc h as ultras o u n d pr oce d ures a n d la b orat or y tests. T he i n vesti gat or’s c o py of t he e C R F ser ves as part of t he i n vesti gat or’s rec or d of a partici pa nt’s st u d y -relate d data."
66,page_66,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 6St u d y a n d Site Cl os ure T he sp o ns or or desi g nee reser ves t he ri g ht t o cl ose t he st u d y site or ter mi nate t he st u d y at a n y ti me f or a ny reas o n at t he s ole discreti o n of t he s p o ns or. T he st u d y site will be cl ose d u p o n st u d y c o m plet i o n. T he st u d y site is c o nsi dere d cl ose d w he n all re q uire d d oc u me nts a n d st u d y s up plies ha ve bee n c ollecte d a n d t he st u d y-site cl os ure visit has bee n perf or me d. T he i n vesti gat or ma y i nitiate st u d y-site cl os ure at a n y ti me, pr o vi de d t here is reas o na ble ca use a n d s ufficie nt n otice is gi ve n i n a d va nce of t he i nte n de d ter mi nati o n. Re as o ns f or t he earl y cl os ure of t he st u d y site by t he s p o ns or or i n vesti gat or ma y i ncl u d e b ut are n ot li mite d t o:  Fail ure of t he i n vesti gat or t o c o m pl y wit h t he pr ot oc ol, t he re q uire me nts of t he IR B/I E C or l ocal healt h a ut h orities, t he s p o ns or ’s pr oce d ures, or G C P g ui deli nes  I na de q uate recr uit me nt of partici pa nt s b y t he i n vesti gat or  Disc o nti n uati o n of f urt her st u d y treat me nt de vel o p me nt"
67,page_67,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 71 2. 4. A p pe n di x 4: A d verse E ve nts: Defi niti o ns a n d P r oce d ures f or Rec or di n g, E v al u ati n g, F oll o w -u p , a n d Re p orti n g Defi niti o n of A E A E Defi niti o n  A n A E is a n y u nt o war d me dical occ urre nce i n a patie nt or cli nical st u d y partici pa nt, te m p orall y ass ociate d wit h t he use of st u d y treat me nt, w het her or n ot c o nsi dere d relate d t o t he st u d y treat me nt.  N O T E: A n A E ca n t heref ore be a n y u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y fi n di n g), sy m pt o m, or disease ( ne w or e xacer bate d) te m p orall y ass ociate d wit h t he use of st u d y treat me nt. A E of S peci al I nterest ( A E SI) A n A E of s pecial i nterest (seri o us or n o nseri o us) is o ne of scie ntific a n d me dical c o ncer n s pecific t o t he sp o ns or’s st u d y dr u g/ de vice or pr o gra m, w hic h warra nts o n g oi n g m o nit ori n g a n d ra pi d c o m m u nicati o n b y t he i n vesti gat or t o t he s p o ns or. S uc h a n e ve nt mi g ht warra nt f urt her i n vesti gati o n i n or der t o c haracterize a n d u n dersta n d it. T he f oll o wi n g A E SIs ha ve bee n i de nt ifie d f or t he st u d y treat me nt i n t his pr ot oc ol: S O s pas m, pa ncreatitis, a n d se vere c o nsti pati o n.  If a partici pa nt is s us pecte d of e x perie nci n g a n A E SI (i.e. pa ncreatitis, S O s pas m, or se vere c o nsti pati o n), t he A E m ust be re p orte d t o t he s p o ns or's S A E mail b o x: I R-Cli nical -S A E @aller ga n.c o m wit hi n 2 4 h o urs o n a n S A E F or m f or Cli nical Trials; i n t he a bse nce of sca n ni n g or e maili n g, t he S A E f or m ma y be fa xe d t o + 1 -7 1 4 -7 9 6 -9 5 0 4."
68,page_68,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 8E ve nts M eeti n g t he A E D efi niti o n  A n y a b n or mal la b orat or y test res ults ( he mat ol o g y, cli nical c he mistr y, or uri nal ysis) or ot her safet y assess me nts ( e g, electr ocar di o gra ms [ E C G s], ra di ol o gical sca ns, vital si g ns meas ure me nts), i ncl u di n g t h ose t hat w orse n fr o m baseli ne, c o nsi dere d cli nicall y si g nifica nt i n t he me dical a n d scie ntific j u d g me nt of t he i n vesti gat or (ie, n ot relate d t o pr o gressi o n of u n derl yi n g disease )  E xacer bati o n of a c hr o nic or i nter mitte nt pre -e xisti n g c o n diti o n i ncl u di n g eit her a n i ncrease i n fre q ue nc y a nd/ or i nte nsit y of t he c o n diti o n  Ne w c o n diti o n detecte d or dia g n ose d after st u d y treat me nt a d mi nistrati o n e ve n t h o u g h it ma y ha ve bee n prese nt bef ore t he start of the st u d y  Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d dr u g -dr u g i nteracti o n  Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d o ver d ose of eit her st u d y treat me nt or a c o nc o mita nt me dicati o n. Over d ose per se will n ot be re p orte d as a n A E/ S A E u nless it is a n i nte nti o nal o ver d ose ta ke n wit h p ossi ble s uici dal/self- har mi n g i nte nt. S uc h o ver d oses s h o ul d be re p orte d re gar dless of se q uelae.  Lac k of efficac y or fail ure of e x pecte d p har mac ol o gical acti o n per se will n ot be re p orte d as a n A E or S A E. S uc h i nsta nces will be ca pt ure d i n t he efficac y assess me nts. H o we ver, t he si g ns, s y m pt o ms, a n d/ or cli nical se q uelae res ulti n g fr o m lac k of efficac y will be re p orte d as A E s or S A E s if t he y f ulfil t he defi niti o n of a n A E or S A E. E ve nts N O T Meeti n g t he A E D efi niti o n  A n y cli nicall y si g nifica nt a b n or mal la b orat or y fi n di n gs or ot her a b n or mal safety assess me nts t hat are ass ociate d wit h t he u n derl yi n g disease, u nless j u d ge d b y t he i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt ’s c o n diti o n  T h e disease/ dis or der bei n g st u die d or e x pecte d pr o gressi o n, si g ns, or sy m pt o ms (clearl y defi ne d) of t he disease/ dis or der bei n g st u die d, u nless m ore se vere t ha n e x pecte d f or t he partici pa nt ’s c o n diti o n  Me dical or s ur gical pr oce d ure ( e g, e n d osc o p y, a p pe n dect o my): t he c o n diti o n t hat lea ds t o t he pr oce d ure is t he A E  Sit uati o ns i n w hic h a n u nt o war d me dical occ urre nce di d n ot occ ur (s ocial a n d/ or c o n ve nie nce a d missi o n t o a h os pital)  A ntici pate d da y -t o-d a y fl uct uati o ns of pre-e xisti n g disease(s) or c o n diti o n(s) prese nt or detecte d at t he start of t he st u d y t hat d o n ot w orse n"
69,page_69,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 6 9Defi niti o n of S A E If a n e ve nt is n ot a n A E per t he defi niti o n a b o ve, t he n it ca n n ot be a n S A E e ve n if seri o us c o n diti o ns are met ( e g, h os pitalizati o n f or si g ns/s y m pt o ms of t he disease u n der st u d y , deat h d ue t o pr o gressi o n of disease). A n S A E is defi ne d as a n y u nt o w ar d me dic al occ urre nce t h at, at a n y d ose: a. Res ults i n de at h b. Is life t hre ate ni n g T he ter m life t hre ate ni n g i n t he defi niti o n of seri o us refers t o a n e ve nt i n w hic h t he partici pa nt was at ris k of deat h at t he ti me of t he e ve nt. It d oes n ot refer t o a n e ve nt, w hic h h y p ot heticall y mi g ht ha ve ca use d deat h, if it were m ore se vere. c. Re q uires i n p atie nt h os pit aliz ati o n or pr ol o n g ati o n of e xisti n g h os pit aliz ati o n I n ge neral, h os pitalizati o n si g nifies t hat t he partici pa nt has bee n detai ne d ( us uall y i n v ol vi n g at least a n o ver ni g ht sta y) at t he h os pital or e mer ge nc y war d f or o bser vati o n a n d/ or treat me nt t hat w o ul d n ot ha ve bee n a p pr o priate i n t he p h ys icia n’s office or o ut patie nt setti n g. C o m plicati o ns t hat occ ur d uri n g h os pitalizati o n are A E s. If a c o m plicati o n pr ol o n gs h os pitalizati o n or f ulfills a n y ot her seri o us criteria, t he e ve nt is seri o us. W he n i n d o u b t as to w het her h os pitalizati o n occ urre d or was necessar y , t he AE s h o ul d be c o nsi dere d seri o us. H os pitalizati o n f or electi ve treat me nt of a pre -e xisti n g c o n diti o n t hat di d n ot w orse n fr o m baseli ne is n ot c o nsi dere d a n A E. d. Res ults i n persiste nt dis a bilit y/ i nc a p acit y  T he ter m disa bilit y mea ns a s u bsta ntial disr u pti o n of a pers o n’s a bilit y t o c o n d uct n or mal life f u ncti o ns. T his defi niti o n is n ot i nte n de d t o i ncl u de e x perie nces of relati vel y mi n or me dical si g nifica nce s uc h as u nc o m plicate d hea dac he, na usea, v o miti n g, diarr hea, i nfl ue nza, a n d acci de ntal tra u ma ( e g, s prai ne d a n kle) w hic h ma y i nterfere wit h or pre ve nt e ver yd a y life f u ncti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pti o n. e. Is a c o n ge nit al a n o m al y/ birt h defect f. Ot her sit u ati o ns:  Me dical or scie ntific j u d g me nt s h o ul d be e xercise d i n deci di n g w het her S A E re p orti n g is a p pr o priate i n ot her sit uati o ns s uc h as i m p orta nt me dical e ve nts t hat ma y n ot be i m me diatel y life t hreate ni n g or res ult i n deat h or h os pitalizati o n b ut ma y je o par dize the partici pa nt or ma y re q uire me dical or s ur gical i nter ve nti o n t o pre ve nt o ne of t he ot her o utc o mes liste d i n t he a b o ve defi niti o n. T hese e ve nts s h o ul d us uall y be c o nsi dere d seri o us ."
70,page_70,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 0E xa m ples of s uc h e ve nts i ncl u de i n vasi ve or mali g na nt ca ncers, i nte nsi ve treat me nt i n a n e mer ge nc y r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d yscrasias or c o n v ulsi o ns t hat d o n ot res ult i n h os pitalizati o n, or de vel o p me nt of dr u g de pe n de nc y or dr u g a b use. Rec or di n g a n A E a n d / or S A E A E a n d S A E Rec or di n g  W he n a n A E/ S A E oc c urs, it is t he res p o nsi bilit y of t he i n vesti gat or t o re vie w all d oc u me ntati o n ( e g, h os pital pr o gress n otes, la b orat or y re p orts, a n d dia g n ostics re p orts) relate d t o t he e ve nt.  T he i n vesti gat or will t he n rec or d all rele va nt A E/ S A E i nf or mati o n i n t he C R F.  It is n ot acce pta ble f or t he i n vesti gat or t o se n d p h ot oc o pies of t he partici pa nt ’s me dical rec or ds t o t he s p o ns or i n lie u of c o m pleti o n of t he A E/ S A E C R F pa ge.  T here ma y be i nsta nces w he n c o pies of me dical rec or ds f or certai n cases are re q ueste d by t he s p o ns or. I n t his case, all partici pa nt i de ntifiers, wit h t he e xce pti o n of t he partici pa nt n u m ber, will be re dacte d o n t he c o pies of t he me dical rec or ds bef ore s u b missi o n t o t he s p o ns or. T he i n vesti gat or will atte m pt t o esta blis h a dia g n osis of t he e ve nt base d o n si g ns, s ym pt o ms, a n d/ or ot her cli nical i nf or mati o n. W he ne ver p ossi ble , t he dia g n osis ( n ot t he i n di vi d ual si g ns/s ym pt o ms) will be d oc u me nte d as t he A E/ S A E . Assess me nt of I nte nsit y MI L D A t y pe of a d verse e ve nt t hat is us uall y tra nsie nt a n d ma y re q uire o nl y mi ni mal treat me nt or t hera pe utic i nter ve nti o n. T he e ve nt d oes n ot ge nerall y i nterfere wit h us ual acti vities of dail y li vi n g. M O D E R A T E A t y pe of a d verse e ve nt t hat is us uall y alle viate d wit h a d diti o nal s pecific t hera pe utic i nter ve nti o n. T he e ve nt i nterferes wit h us ual acti vities of dail y li vi n g, ca usi n g disc o mf ort b ut p oses n o si g nifica nt or per ma ne nt ris k of har m t o t he researc h partici pa nt. S E V E R E A t y pe of a d verse e ve nt t hat i nterr u pts us ual acti vities of dail y li vi n g, or si g nifica ntl y affects cli nical stat us, or ma y re q uire i nte nsi ve t hera pe utic i nter ve nti o n. A n e ve nt is defi ne d as seri o us w he n it meets at least 1 of t he pre defi ne d o utc o mes as descri be d i n t he defi niti o n of a n S A E , N O T w he n it is rate d as se vere."
71,page_71,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 1Assess me nt of C a us alit y  T he i n vesti gat or is o bli gate d t o assess t he relati o ns hi p bet wee n st u d y treat me nt a n d eac h occ urre nce of eac h A E/ S A E.  A re as o n a ble p ossi bility of a relati o ns hi p c o n ve ys t hat t here are facts, e vi de nce , a n d/ or ar g u me nts t o s u g gest a ca usal relati o ns hi p, rat h er t ha n a relati o ns hi p ca n n ot be r ule d o ut.  T he i n vesti gat or will use cli nical j u d g me nt t o deter mi ne t he relati o ns hi p.  Alter nati ve ca uses, s uc h as u n derl yi n g disease (s), c o nc o mita nt t hera py, a n d ot her ris k fact ors, as well as t he te m p oral relati o ns hi p of the e ve nt t o st u d y treat me nt a d mi nistrati o n will be c o nsi dere d a n d i n vesti gate d.  T he i n vesti gat or will als o c o ns ult t he I B a n d/ or pr o d uct i nf o r mati o n, f or mar kete d pr o d ucts, i n his/ her assess me nt.  F or eac h A E/ S A E , t he i n vesti gat or m ust d oc u me nt i n t he me dical n otes t hat he/s he has re vie we d t he A E/ S A E a n d has pr o vi de d a n assess me nt of ca usalit y .  T here ma y be sit uati o ns i n w hic h a n S A E has occ urre d a n d t he i n vesti gat or has mi ni mal i nf or mati o n t o i ncl u de i n t he i nitial re p ort t o t he s p o ns or. H o we ver, it is ver y i m p ort a nt t h at t he i n vesti g at or al w a ys m a ke a n assess me nt of c a us alit y f or e ver y e ve nt bef ore t he i niti al tr a ns missi o n of t he S A E d at a t o t he s p o ns or.  T he i n vesti gat or ma y c ha n ge his/ her o pi ni o n of ca usalit y i n li g ht of f oll o w-u p i nfor mati o n a n d se n d a n S A E f oll o w -u p re p ort wit h t he u p date d ca usalit y assess me nt . T he ca usalit y assess me nt is o ne of t he criteria use d w he n deter mi ni n g re g ulat or y re p orti n g re q uire me nts. Re p orti n g of S A E s S A E R e p orti n g t o t he S p o ns or vi a a n E lectr o nic D at a C ollecti o n T o ol  T he p ri mar y mec ha nis m f or re p orti n g a n S A E t o t he s p o ns or will be t he electr o nic data c ollecti o n t o ol .  If t he electr o nic sys te m is u na vaila ble f or m ore t ha n 2 4 h o urs, t hen t he site will use t he pa per S A E data c ollecti o n t o ol (see ne xt secti o n).  T he s ite will e nter t he S A E data i nt o t he electr o nic s y ste m as s o o n as it bec o mes a vaila ble.  After t he st u d y is c o m plete d at t he site, t he electr o nic data c ollecti o n t o ol will be ta ke n off-li ne t o pre ve nt t he e ntr y of ne w data or c ha n ges t o e xisti n g data.  If t he site recei ves a re p ort of a ne w S A E fr o m a st u d y partici pa nt or recei ves u p date d data o n a pre vi o usl y re p orte d S A E after t he electr o nic data c ollecti o n t o ol"
72,page_72,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 2has bee n ta ke n off -li ne, t hen t he site ca n re p ort t his i nf or mati o n o n a pa per S A E f or m (see ne xt secti o n) or t o t he s p o ns or b y tele p h o ne. C o ntacts f or S A E re p orti n g ca n be f o u n d i n t he pr ot oc ol title pa ge. S A E Re p orti n g t o t he S p o ns or vi a P a per C R F  Facsi mile tra ns missi o n of t he S A E pa per C R F is t he preferre d met h o d t o t ra ns mit t his i nf or mati o n t o t he s p o ns or.  I n rare circ u msta nces a n d i n t he a bse nce of facsi mile e q ui p me nt, n otificati o n b y tele p h o ne is acce pta ble wit h a c o py of t he S A E data c ollecti o n t o ol se nt b y o ver ni g ht mail or c o urier ser vice. I nitial n otificati o n via tele p h o ne does n ot re place t he nee d f or t he i n vesti gat or t o c o m plete a n d si g n t he S A E C R F pa ges wit hin t he desi g nate d re p orti n g ti me fra mes. C o ntacts f or S A E re p orti n g ca n be f o u n d i n t he pr ot oc ol title pa ge."
73,page_73,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 3
74,page_74,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 4
75,page_75,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 5
76,page_76,C O N FI D E N TI A L El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 6
77,page_77,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 7
78,page_78,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 81 2. 7. A p pe n di x 7 : St a n d ar d Disc o nti n u ati o n Criteri a C DI S C S u b missi o n V al ue C DI S C Defi niti o n A d verse e ve nt A n y u nt o war d me dical occ urre nce i n a patie nt or cli nical i n vesti gati o n s u bject a d mi nistere d a p har mace utical pr o d uct a n d w hic h d oes n ot necessaril y ha ve a ca usal relati o ns hi p wit h t his treat me nt. A n a d verse e ve nt ( A E) ca n t heref ore be a n y u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y fi n di n g), s y m pt o m, or disease te mp orall y ass ociate d wit h t he use of a me dici nal (i n vesti gati o nal) pr o d uct, w het her or n ot relate d t o t he me dici nal (i n vesti gati o nal) pr o d uct. F or f urt her i nf or mati o n, see t he I C H G ui deli ne f or Cli nical Safet y Data Ma na ge me nt: Defi niti o ns a n d Sta n dar ds f or E x pe dite d Re p orti n g. [ M o difie d fr o m I C H E 2 A] S y n o n y ms: si de effect, a d verse e x perie nce. See als o seri o us a d verse e ve nt ( S A E), seri o us a d verse e x perie nce ( Cli nical Data I nterc ha n ge Sta n dar ds C o ns orti u m [ C DI S C] gl ossar y) C o m plete d T o p ossess e ver y necessar y or n or mal part or c o m p o ne nt or ste p; ha vi n g c o me or bee n br o u g ht t o a c o ncl usi o n (Nati o nal Ca ncer I nstit ute [ N CI ]) Deat h T he a bse nce of life or state of bei n g dea d ( N CI) Lac k of efficac y T he lac k of e x pecte d or desire d effect relate d t o a t hera p y ( N CI) L ost t o f oll o w -u p T he l oss or lac k of c o nti n uati o n of a s u bject t o f oll o w-u p N o n -c o mplia nce wit h st u d y dr u g A n i n dicati o n t hat a s u bject has n ot a gree d wit h or f oll o we d t he i nstr ucti o ns relate d t o t he st u d y me dicati o n ( N CI) Ot her Differe nt t ha n t he o ne(s) pre vi o usl y s pecifie d or me nti o ne d ( N CI) P h y sicia n decisi o n A p ositi o n, o pi ni o n or j u d g me nt reac he d after c o nsi derati o n b y a p h ysicia n wit h refere nce t o s u bject ( N CI) Pre g na nc y Pre g na nc y is t he state or c o n diti o n of ha vi n g a de vel o pi n g e m br y o or fet us i n t he b o d y ( uter us), after u ni o n of a n o v u m a n d s per mat oz o o n, d uri n g t he peri o d fr o m c o nce pti o n t o birt h. ( N CI) Pr ot oc ol de viati o n A n e ve nt or decisi o n t hat sta n ds i n c o ntrast t o t he g ui deli nes set o ut b y t he pr ot oc ol ( N CI) Scree n fail ure T he p ote ntial s u bject w h o d oes n ot meet o ne or m o re criteria re q uire d f or partici pati o n i n a trial"
79,page_79,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 7 9C DI S C S u b missi o n V al ue C DI S C Defi niti o n Site ter mi nate d b y s p o ns or A n i n dicati o n t hat a cli nical st u d y was st o p pe d at a partic ular site b y its s p o ns or ( N CI) St u d y ter mi nate d b y s p o ns or A n i n dicati o n t hat a cli nical st u d y was st o p pe d b y its s p o ns or ( N CI) Wit h dra w al b y s u bject A n i n dicati o n t hat a st u d y partici pa nt has re m o ve d itself fr o m t he st u d y (N CI)
80,page_80,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 01 2. 8. A p pe n di x 8 : St u d y T a b ul ar S u m m ar y P a r a m eter Gr o u p P a r a m eter V al ue Trial i nf or mati o n Trial Title 3 0 3 0 -4 0 1 -0 0 2: A n O pe n -La bel Pil ot St u d y of El u xa d oli ne i n Partici pa nts wit h Irrita ble B o w el S y n dr o me wit h Diarr hea (I B S -D) W h o Ha ve E vi de nce of Bile Aci d Mala bs or pti o n ( B A M) Cli nical St u d y S p o ns or Aller ga n Trial P hase Classificati o n P hase 4 Trial I n dicati o n I B S- D Trial I n dicati o n T y pe Treat me nt Trial T y pe Efficac y Safet y Trial Le n gt h U p t o 1 1 w ee ks, w hic h i ncl u des: scree ni n g peri o d ( 0 -2 we e ks), pretreat me nt peri o d ( 2-3 w ee ks), 4-wee k o pe n -la bel treat me nt peri o d a n d 2 -we e k p ost -treat me nt f oll o w-u p peri o d. Pla n ne d C o u ntr y of I n vesti gati o nal Site U nite d States Pla n ne d N u m ber of Partici pa nt s 2 4 F D A -Re g ulate d De vice St u d y I n dicat or N o F D A -Re g ulate d Dr u g St u d y I n dicat or N o Pe diatric St u d y I n dicat or N o Partici pa nt i nf or mati o nDia g n osis Gr o u p Partici pa nts wit h I B S-D w h o ha ve evi de nce of B A M Healt h y Partici pa nt I n dicat or N o Pla n ne d Mi ni m u m A ge of Partici pa nts 1 8 Pla n ne d Ma xi m u m A ge of Partici pa nts 6 5 Se x of Partici pa nts B ot h Sta ble Disease Mi ni m u m D urati o n A dia g n osis of I B S f ulfille d f or t he last 3 m o nt hs pri or t o s cree ni n g wit h s y m pt o m o nset at least 6 m o nt hs bef ore dia g n osis as defi ne d b y t he R o me I V criteria f or I B S. Treat me nts I n vesti gati o nal T hera p y or Treat me nt El u xa d oli ne I nter ve nti o n Ty pe Dr u g P har mac ol o gical Class of I n vesti gati o nal T hera p yL ocall y acti ve mi xe d m u -o pi oi d rece pt or ( µ O R) a g o nist, ka p pa-o pi oi d rece pt or"
81,page_81,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 1P a r a m eter Gr o u p P a r a m eter V al ue ( κ O R) a g o nist, a n d delta-o pi oi d rece pt or ( δ O R) a nta g o nist. D ose per A d mi nistrati o n 1 0 0 m g D ose U nits 1 0 0 m g D osi n g Fre q ue nc y BI D R o ute of A d mi nistrati o n Oral C urre nt T hera p y or Treat me nt N o ne A d de d o n t o E xisti n g Treat me nts N o C o ntr ol T y pe N/ A C o m parati ve Treat me nt Na me N/ A Trial desi g n St u d y T y pe I nter ve nti o nal I nter ve nti o n M o del O pe n -La bel , pil ot Pla n ne d N u m ber of Ar ms 1 Pla n ne d N u m ber of C o h orts 2 Trial is Ra n d o mize d N o Ra n d o mizati o n Q u otie nt N/ A Trial Bli n di n g Sc he ma N o ne Stratificati o n Fact or Wit h a n d wit h o ut e vi de nce of B A M A da pti ve Desi g n N o St u d y St o p R ules Partici pa nts m ust pre mat urel y disc o nti n ue st u d y treat me nt f or reas o ns of safet y i ncl u di n g:  a n S A E c o nsi dere d b y t he in vesti gat or or t he s p o ns or t o be p ossi bl y relate d or relate d t o i n vesti gati o nal pr o d uct,  a n A E of s pecial i nterest ( S O s pas m, pa ncreatitis , se vere c o nsti pati o n)  pre g na nc y  si g ns of dr u g-i n d uce d li ver i nj ur y ( DI LI) o utli ne d i n A p pe n di x 6 Secti o n 1 2. 6 , Li ver Safet y Partici pa nts ma y pr e m at urel y disc o nti n ue st u d y treat me nt f or reas o ns of safet y i ncl u di n g:  t he prese nce of i nte nti o nal o verd ose or i nte nti o nal mis use per in vesti gat or discreti o n,"
82,page_82,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 2P a r a m eter Gr o u p P a r a m eter V al ue  a n A E i n dicati ve of a C N S o pi oi d effect, e g, pi n p oi nt p u pils, l oss of c o nsci o us ness, deliri u m, se dati o n or s o m n ole nce, e u p h oric, a n xi o us or de presse d m o o d, t hat i n t he o pi n i o n of t he in vesti gat or or t he s p o ns or is p ossi bl y relate d or relate d t o t he i n vesti gati o nal pr o d uct,  a vital si g n, a n d/ or la b orat or y a b n or malit y j u d ge d t o be cli nicall y si g nificant b y t he i n vesti gat or a n d t hat i n t he o pi ni o n of t he in vesti gat or or t he sp o ns or is p ossi bl y relate d or relate d t o t he i n vesti gati o nal pr o d uct,  a n i nt olera ble A E ( defi ne d as a n A E t hat s u bjecti vel y w o ul d ca use a partici pa nt t o c o nsi der st u d y wit h dra wal),  a n a bse nce of b o wel m o ve me nts f or ≥ 3 c o nsec uti ve da ys, base d o n res p o nses rec or de d via e Diar y,  t he use of a n e xcessi ve a m o u nt of l o pera mi de resc ue me dicati o n,  t he occ urre nce of a n y ot her A E t hat i n t he o pi ni o n of t he in vesti gat or or t he sp o ns or is p ossi bl y relate d or relate d t o t he st u d y treat me nt t hat re prese nts a cli nicall y si g nifica nt safet y ris k t o t he partici pa nt ."
83,page_83,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 3
84,page_84,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 4
85,page_85,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 5
86,page_86,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 6
87,page_87,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 7
88,page_88,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 81 2. 1 0. A p pe n di x 1 0 : S u m m ar y A d a pte d fr o m G ui deli nes of t he U S M ulti - s ociet y T as k F orce o n C ol orect al C a ncer a n d Ot her C ol o n osc o p y Re q uire me nts N ote: Partici pa nt m a y be e nr olle d if n o f oll o w-u p c ol o n osc o p y after p ol yp re m o val is d ue w hile partici pati n g i n t he st u d y. 1. Partici pa nt s a ge 5 0 ye ars ( 4 0 years if Africa n A merica n) a n d ol der m ust ha ve ha d a c ol o n osc o p y wit h ne g ati ve fi n di n gs wi t hi n t he 1 0 years pri or t o t he scree ni n g v isit ( Visit 1). 2. If t he m ost rece nt c ol o n osc o p y re veale d h yper plastic p ol y ps t hat were e ntirel y re m o ve d, t he partici pa nt m a y be e nr olle d, pr o vi de d t he c ol o n osc o p y was perf or med wit hi n 1 0 y ears pri or t o t he scree ni n g visit ( Visit 1). 3. If t he m ost rece nt c ol o n osc o p y re veale d 2 or fe wer s mall ( < 1 c m) a de n o mat o us p ol yps wit h t u b ular str uct ure wit h l o w gra de dys plasia a n d wit h o ut a p precia ble vill o us tiss ue, t he partici pa nt m a y be e nr olle d, pr o vi de d t he c ol o n osc o p y was perf or me d wit hi n 5 years pri or t o t he scree ni n g visit ( Visit 1). 4. Partici pa nt s w h o ha ve 1 first-de gree relati ve wit h c ol orectal ca ncer or a de n o mat o us p ol y ps dia g n ose d bef ore a ge 6 0 or 2 first- de gree relati ves wit h c ol orectal ca ncer dia g n ose d a t a ny a ge, m ust ha ve ha d a c ol o n osc o p y wit h ne gati ve fi n di n gs 5 years bef ore t h e scree ni n g v isit ( Visit 1). T his a p plies t o partici pa nt s w h o are 4 0 years or ol der a n d t o partici pa nt s yo u n ger t ha n 4 0 years, w h o are 1 0 or fe wer years fr o m t he a ge at w hic h t h eir y o u n gest relati ve was f o u n d t o ha ve 1 of t he af ore me nti o ne d c o n diti o ns. 5. Partici pa nt s w h o ha ve 1 first-de gree relati ve wit h c ol orectal ca ncer or a de n o mat o us p ol y ps dia g n ose d at a ge 6 0 or ol der or 2 sec o n d -de gree relati ves wit h c ol orectal ca ncer dia g n ose d at a n y a ge, m ust ha ve ha d a c ol o n osc o p y wit h ne gati ve fi n di n gs wit hi n 1 0 years pri or t o t he scree ni n g visit ( Visit 1). T his a p plies t o partici pa nt s w h o are 4 0 ye ars or ol der a n d t o partici pa nt s yo u n ger t ha n 4 0 y ears, w h o are 1 0 or fe wer years fr o m t he a g e at w hic h t heir y o u n gest relati ve was f o u n d t o ha ve 1 of t he af ore me nti o ne d c o n diti o ns. Ot her C ol o n osc o p y Re q uire me nts: Partici pa nt s of a ny a ge w h o ha ve alar m s y m pt o ms m ust ha ve ha d a c ol o n osc o p y wit h ne gati ve fi n di n gs after t he o nset of t he alar m sy m pt o ms a n d wit hi n 5 y ears pri or t o t he scree ni n g v isit ( Visit 1). Alar m sy m pt o ms i ncl u de l o wer GI blee di n g (rectal blee di n g or he me -p ositi ve st o ol), ir o n-deficie nc y a ne mia, a n d wei g ht l oss. (N ote: C urre nt u ne x plai ne d or cli nicall y si g nifica nt alar m s y m pt o ms ar e e xcl usi o nar y.) T hese re q uire me nts are a da pte d base d o n rece nt G ui da nce o n C ol orectal Ca ncer Scree ni n g (Le vi n 2 0 0 8 ; Li e ber ma n 2 0 1 2 ; Qasee m 2 0 1 2 ). Refere nces Le vi n B, Lie ber ma n D A, Mc Farla n d B, A n dre ws K S, Br o o ks D, B o n d J et al . Scree ni n g a n d S ur veilla nce f or t he Earl y Detecti o n of C ol orectal Ca ncer a n d A de n o mat o us P ol yps, 2 0 0 8: A J oi nt G ui deli ne Fr o m t he A merica n Ca ncer S ociet y , t he U S M ulti-S ociet y T as k F orce o n C ol orectal Ca ncer, a n d t he A merica n C olle ge of Ra di ol o g y . Gastr oe nter ol o g y . 2 0 0 8; 1 3 4: 1 5 7 0 -1 5 9 5 ."
89,page_89,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 8 9Lie ber ma n D A, Re x D K, Wi na wer SJ, Giar diell o F M, J o h ns o n D A, Le vi n T R. G ui deli nes f or C ol o n osc o p y Sur veilla nce After Scree ni n g a n d P ol y pect o m y : A C o nse ns us U p date b y t he U S M ulti -S ociet y Tas k F orce o n C ol orectal Ca ncer . G astr oe nter ol o g y. 2 0 1 2; 1 4 3: 8 4 4 – 8 5 7 . Qasee m A, De n ber g T D, H o p ki ns Jr R H, H u m p hre y L L, Le vi ne J, S weet D E, S he kelle P . Scree ni n g f or C ol orectal Ca ncer : A G ui da nce State me nt Fr o m t he A merica n C olle ge of P h y sicia ns. A n n I nter n Me d. 2 0 1 2; 1 5 6: 3 7 8 -3 8 6."
90,page_90,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 01 2. 1 1. A p pe n di x 1 1: Brist ol St o ol F or m Sc ale ( B S F S) T y p e 1 - S e p ar at e h ar d l u m p s li k e n ut s ( diffi c ult t o p a s s) T y p e 2 - S a u s a g e s h a p e d b ut l u m p y T y p e 3 - Li k e a s a u s a g e b ut wit h cr a c k s o n s urf a c e T y p e 4 - Li k e a s a u s a g e or s n a k e, s m o ot h a n d s oft T y p e 5 - S oft bl o b s wit h cl e ar -c ut e d g e s ( p a s s e d e a sil y) T y p e 6 - Fl uff y pi e c e s wit h r a g g e d e d g e s, a m u s h y st o ol T y p e 7 - W a t er y, n o s oli d pi e c e s ( e ntir el y li q ui d)"
91,page_91,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 1
92,page_92,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 2
93,page_93,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 3
94,page_94,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 4
95,page_95,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 5
96,page_96,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 6
97,page_97,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 7
98,page_98,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 8
99,page_99,El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 9 9
100,page_100,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 0 01 2. 1 3. Pr ot oc ol A me n d me nt 1 S u m m ar y Secti o n N o. a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale Secti o n 1 S y n o psis ( St u d y desi g n ta ble); Secti o n 2 S O A; Secti o n 5. 1 Ta ble 5- 1A d diti o n of b ol de d te xt t o f o ot n ote (f o ot n ote a i n s y n o psis a n d f o ot n ote b i n S O A): Scree ni n g a n d Pretreat me nt peri o ds ma y be c o m bi ne d, if res ults of fasti n g ser u m 7 α C 4 test or 4 8 -h o ur fecal B A c ollecti o n c o n d ucte d wit hi n 1 cale n dar year fr o m Scree ni n g Visit are a vaila ble at t he ti me of t he c o m bi ne d visit or res ults fr o m f asti n g ser u m 7 α C 4 test are a v ail a ble pri or t o t he st art of st u d y tre at me nt. Secti o n 9 Scree ni n g Visit 1 A d diti o n of b ol de d te xt: T his visit ma y be c o m bi ne d wit h t he pretreat me nt visit if res ults fr o m a fasti n g ser u m 7 α C 4 test or 4 8 -h o ur fecal B A c ollecti o n, c o n d ucte d wit hi n 1 cale n dar year pri or t o scree ni n g, are a vaila ble at t he ti me of t he c o m bi ne d visit or res ults fr o m f asti n g ser u m 7 α C 4 test are a v ail a ble pri or t o t he st art of st u d y tre at me nt. T he scree ni n g visit will occ ur a p pr o xi matel y 2 t o 3 w ee ks bef ore t he first d ose of st u d y dr u g (if c o mbi ne d wit h pretre at me nt visit) a n d n o m ore t ha n 5 wee ks bef ore t he first d ose of st u d y dr u g, if t he partici pa nt re q uires a n a d diti o nal wee k f or eac h, scree ni n g a n d pretreat me nt pr oce d ures).T he ori gi nal pr ot oc ol all o w e d scree ni n g a n d pretreat me nt visits t o be c o m bi ne d f or partici pa nt w h o ha d hist orical res ults of fasti n g ser u m 7 α C 4 test or 4 8-h o ur fecal B A c ollecti o n a vaila ble wit hi n 1 cale n dar year fr o m scree ni n g. T he t ur nar o u n d f or 7 α C 4 res ults use d t o be a p pr o xi matel y 2-3 wee ks. T he 7 α C 4 test res ults are n o w a vaila ble i n a p pr o xi matel y 1 wee k w hic h was a tri g ger t o all o w c o mbi ni n g Scree ni n g a n d Pretreat me nt f or all st u d y partici pa nts. T his will all o w fe wer visits f or s o me partici pa nts, decreasi n g t he partici pa nt b ur de n. Secti o n 9 Pretreat me nt ( Visit 2)A d diti o n of b ol de d te xt: T his visit ma y be c o m bi ne d wit h t he scree ni n g visit if res ults fr o m a fasti n g ser u m 7 α C 4 test or 4 8 -h o ur fecal B A c ollecti o n, c o n d ucte d wit hi n 1 cale n dar year pri or t o scree ni n g, are a vaila ble at t he ti me of t he c o m bi ne d visit or res ults fr o m f asti n g ser u m 7 α C 4 test are a v ail a ble pri or t o t he st art of st u d y tre at me nt."
101,page_101,"El u xa d oli nePr ot oc ol 3 0 3 0 -4 0 1 -0 0 2 1 0 1Secti o n N o. a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale Secti o n 5. 1 D urati o n of scree ni n g peri o d c ha n ge d t o 1 0 -2 w ee ks a n d defi ne d as Wee k - 3 t o -4 5 pri or t o B aseli ne Visit ( V 3, St u d y D a y 1)T o c orrect i nacc urac y i n ori gi nal pr ot oc ol Secti o n 7. 5 A d diti o n of b ol de d te xt descri bi n g destr ucti o n of test material: T he st u d y site m ust se n d a n y u n use d st u d y treat me nt t o t he ve n d or s pecifie d, f or destr ucti o n or h a ve st u d y dr u g destr o ye d per d oc u me nte d i nstit uti o n al st a n d ar ds of pr actice t h at h a ve bee n a p p r o ve d b y t he s p o ns or.D ue t o D E A ha n dli n g restricti o ns a n d i nsti uti o n pr ocesses t he site is u na blet o ret ur n u n use d st u d y dr u g t o s p o ns or. T he alter nati ve destr ucti o n pr ocess was a gree d u p o n a n d d oc u me nte d i n N ote t o file Secti o n 9. 8. 2. 1 A Es of S pecial I n terestA d diti o n of b ol de d te xt f or clarificati o n: O nce n otifie d, t he i n vesti gat or m ust c o ntact t he partici pa nt t o re vie w t he partici pa nt’s stat us as s o o n as p ossi ble (e g, wit hi n 2 4 h o urs), t o assess t he se verit y of his/ her c o nsti pati o n or t he prese nce of a n y se q uelae of c o nsti pati o n. E ver y atte m pt s h o ul d be m a de t o re ac h t he st u d y p artici p a nt wit hi n 2 4 h o urs .F or clarit y: Se vere c o nsti pati o n is a n a d verse e ve nt of s pecial i nterest a n d d ue to t he p ote ntial seri o us ness of t his c o n diti o n, i n vesti gat or's s h o ul d atte m pt t o reac h t he partici pa nt wit hi n a 2 4 h o ur peri o d. T he pre vi o us iterati o n of t his te xt all o w f or i nter pretati o n of t he p hrase ""as s o o n as p ossi ble"", w hile t he a me n d me nt ma kes it clear t hat "" E ver y atte m pt s h o ul d be ma de t o reac h t he st u d y partici pa nt wit hi n 2 4 h o urs"". Secti o n 1 2. 9 A p pe n di x 9 T he s p o ns or c o ntact i nf or mati o n wa s u p date d. Pers o n nel c ha n ge at Aller ga n"
